ID

DB00195|APRD00245|DB00171|

名称

Betaxolol

描述

A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.

cas号

63659-18-7

唯一标识码

O0ZR1R6RZ2

状态

solid

组

approved,investigational,

指示

For the management of hypertension.

药效学

Betaxolol is a competitive, beta(1)-selective (cardioselective) adrenergic antagonist. Betaxolol is used to treat hypertension, arrhythmias, coronary heart disease, glaucoma, and is also used to reduce non-fatal cardiac events in patients with heart failure. Activation of beta(1)-receptors (located mainly in the heart) by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Drugs such as betaxolol that block these receptors therefore have the reverse effect: they lower the heart rate and blood pressure and hence are used in conditions when the heart itself is deprived of oxygen. They are routinely prescribed in patients with ischemic heart disease. In addition, beta(1)-selective blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. Betaxolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane stabilizing activity.

作用机制

Betaxolol selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Betaxolol can also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles, causing bronchospasm.

毒性

Oral LD₅₀s are 350 to 400 mg betaxolol/kg in mice and 860 to 980 mg/kg in rats. Predicted symptoms of overdose include bradycardia, congestive heart failure, hypotension, bronchospasm, and hypoglycemia.

代谢

Primarily hepatic. Approximately 15% of the dose administered is excreted as unchanged drug, the remainder being metabolites whose contribution to the clinical effect is negligible.

吸收

Absorption of an oral dose is complete. There is a small and consistent first-pass effect resulting in an absolute bioavailability of 89% ± 5% that is unaffected by the concomitant ingestion of food or alcohol.

半衰期

14-22 hours

分类

description:This compound belongs to the class of organic compounds known as tyrosols and derivatives. These are compounds containing a hydroxyethyl group attached to the C4 carbon of a phenol group.
direct-parent:Tyrosols and derivatives
kingdom:Organic compounds
superclass:Benzenoids
class:Phenols
subclass:Tyrosols and derivatives
alternative-parent:1,2-aminoalcohols
alternative-parent:Alkyl aryl ethers
alternative-parent:Dialkyl ethers
alternative-parent:Dialkylamines
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organopnictogen compounds
alternative-parent:Phenol ethers
alternative-parent:Phenoxy compounds
alternative-parent:Secondary alcohols
substituent:1,2-aminoalcohol
substituent:Alcohol
substituent:Alkyl aryl ether
substituent:Amine
substituent:Aromatic homomonocyclic compound
substituent:Dialkyl ether
substituent:Ether
substituent:Hydrocarbon derivative
substituent:Monocyclic benzene moiety
substituent:Organic nitrogen compound
substituent:Organic oxygen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Phenol ether
substituent:Phenoxy compound
substituent:Secondary alcohol
substituent:Secondary aliphatic amine
substituent:Secondary amine
substituent:Tyrosol derivative

消除途径

种类

Adrenergic Agents
D018663
Adrenergic Antagonists
D018674
Adrenergic beta-1 Receptor Antagonists
D058671
Adrenergic beta-Antagonists
D000319
Agents causing hyperkalemia

Alcohols
D000438
Amines
D000588
Amino Alcohols
D000605
Antiarrhythmic agents
D000889
Antiglaucoma Preparations and Miotics

Antihypertensive Agents
D000959
Antihypertensive Agents Indicated for Hypertension

Autonomic Agents
D001337
Beta Blocking Agents, Selective

Beta-adrenergic Agents

Beta-Blockers (Beta1 Selective)

Bradycardia-Causing Agents

Cardiovascular Agents
D002317
Cytochrome P-450 CYP1A2 Substrates

Cytochrome P-450 CYP2D6 Substrates

Cytochrome P-450 Substrates

Hypotensive Agents

Moderate Risk QTc-Prolonging Agents

Neurotransmitter Agents
D018377
Ophthalmologicals

Peripheral Nervous System Agents
D018373
Phenoxypropanolamines
D050198
Propanolamines
D011412
Propanols
D020005
QTc Prolonging Agents

Sensory Organs

Sympatholytics
D013565

盐类

DBSALT000328Betaxolol hydrochloride6X97D2XT0O63659-19-8CHDPSNLJFOQTRK-UHFFFAOYSA-N343.889343.191421538

蛋白质结合

50%

清除

同义词

language:english; code:; name;1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol
language:english; code:; name;1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
language:english/spanish; code:inn; name;Betaxolol
language:french; code:inn; name;Bétaxolol
language:latin; code:inn; name;Betaxololum

国际品牌

Betaxon

配送量

产品

name:Betaxolol
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-4932
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2003-10-07
ended-marketing-on:
dosage-form:Tablet, film coated
strength:10 mg/1
route:Oral
fda-application-number:ANDA075541
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol
labeller:Marlex Pharmaceuticals Inc
ndc-id:
ndc-product-code:10135-623
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:10 mg/1
route:Oral
fda-application-number:ANDA075541
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol
labeller:Marlex Pharmaceuticals Inc
ndc-id:
ndc-product-code:10135-624
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:20 mg/1
route:Oral
fda-application-number:ANDA075541
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol
labeller:Akorn, Inc.
ndc-id:
ndc-product-code:17478-705
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2003-04-01
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA075386
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol
labeller:Epic Pharma LLC
ndc-id:
ndc-product-code:42806-038
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-07-20
ended-marketing-on:
dosage-form:Tablet, film coated
strength:10 mg/1
route:Oral
fda-application-number:ANDA075541
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol
labeller:Epic Pharma LLC
ndc-id:
ndc-product-code:42806-039
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-07-20
ended-marketing-on:
dosage-form:Tablet, film coated
strength:20 mg/1
route:Oral
fda-application-number:ANDA075541
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol
labeller:PuraCap Laboratories LLC
ndc-id:
ndc-product-code:24658-700
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-08-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:10 mg/1
route:Oral
fda-application-number:ANDA075541
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol
labeller:PuraCap Laboratories LLC
ndc-id:
ndc-product-code:24658-701
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-08-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:20 mg/1
route:Oral
fda-application-number:ANDA075541
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-753
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-06-27
ended-marketing-on:
dosage-form:Tablet, film coated
strength:10 mg/1
route:Oral
fda-application-number:ANDA078962
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-754
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-06-27
ended-marketing-on:
dosage-form:Tablet, film coated
strength:20 mg/1
route:Oral
fda-application-number:ANDA078962
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol Hydrochloride
labeller:KVK-Tech, Inc.
ndc-id:
ndc-product-code:10702-013
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-11-02
ended-marketing-on:
dosage-form:Tablet, coated
strength:10 mg/1
route:Oral
fda-application-number:ANDA078962
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol Hydrochloride
labeller:KVK-Tech, Inc.
ndc-id:
ndc-product-code:10702-014
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-11-02
ended-marketing-on:
dosage-form:Tablet, coated
strength:20 mg/1
route:Oral
fda-application-number:ANDA078962
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betaxolol Hydrochloride
labeller:Sandoz Inc
ndc-id:
ndc-product-code:61314-245
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2000-05-15
ended-marketing-on:
dosage-form:Solution / drops
strength:5.6 mg/1mL
route:Ophthalmic
fda-application-number:NDA019270
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betoptic
labeller:Alcon
ndc-id:
ndc-product-code:0065-0245
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-10-30
ended-marketing-on:
dosage-form:Solution / drops
strength:5.6 mg/1mL
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betoptic Liq
labeller:Alcon, Inc.
ndc-id:
ndc-product-code:
dpd-id:00695688
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:1997-07-31
dosage-form:Liquid
strength:
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Betoptic Pilo
labeller:ALCON LABORATORIES, INC.
ndc-id:
ndc-product-code:0065-0850
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-09-26
ended-marketing-on:
dosage-form:Kit
strength:
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betoptic S
labeller:ALCON LABORATORIES, INC.
ndc-id:
ndc-product-code:0065-0246
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1996-01-15
ended-marketing-on:
dosage-form:Suspension / drops
strength:2.8 mg/1mL
route:Ophthalmic
fda-application-number:NDA019845
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Betoptic S
labeller:Novartis
ndc-id:
ndc-product-code:
dpd-id:01908448
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:
dosage-form:Suspension
strength:0.25 %
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Betoptic/pilo
labeller:Alcon, Inc.
ndc-id:
ndc-product-code:
dpd-id:02238539
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Suspension
strength:
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Kerlone
labeller:Sanofi Aventis
ndc-id:
ndc-product-code:0025-5101
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1989-10-27
ended-marketing-on:2003-02-06
dosage-form:Tablet, film coated
strength:10 mg/1
route:Oral
fda-application-number:NDA019507
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Kerlone
labeller:Sanofi Aventis
ndc-id:
ndc-product-code:0025-5201
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1989-10-27
ended-marketing-on:2003-02-06
dosage-form:Tablet, film coated
strength:20 mg/1
route:Oral
fda-application-number:NDA019507
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Novo-betaxolol
labeller:Novopharm Limited
ndc-id:
ndc-product-code:
dpd-id:02240050
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Liquid
strength:
route:Ophthalmic
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sandoz Betaxolol
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02235971
ema-product-code:
ema-ma-number:
started-marketing-on:1998-11-27
ended-marketing-on:2017-08-01
dosage-form:Solution
strength:
route:Ophthalmic
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD

混合物

name:Betaxolol
ingredients:Betaxolol
name:Kerlone
ingredients:Betaxolol
name:Kerlone
ingredients:Betaxolol
name:Betaxolol
ingredients:Betaxolol
name:Betaxolol
ingredients:Betaxolol
name:Betaxolol
ingredients:Betaxolol
name:Betaxolol Hydrochloride
ingredients:Betaxolol
name:Betaxolol Hydrochloride
ingredients:Betaxolol
name:Betaxolol
ingredients:Betaxolol
name:Betaxolol
ingredients:Betaxolol
name:Betoptic Pilo
ingredients:Betaxolol + Pilocarpine
name:Betoptic
ingredients:Betaxolol
name:Betoptic S
ingredients:Betaxolol
name:Betaxolol
ingredients:Betaxolol
name:Betaxolol
ingredients:Betaxolol
name:Betaxolol Hydrochloride
ingredients:Betaxolol
name:Betaxolol
ingredients:Betaxolol
name:Betaxolol
ingredients:Betaxolol
name:Betoptic Liq
ingredients:Betaxolol
name:Betoptic/pilo
ingredients:Betaxolol + Pilocarpine
name:Novo-betaxolol
ingredients:Betaxolol
name:Betoptic S
ingredients:Betaxolol
name:Sandoz Betaxolol
ingredients:Betaxolol

包装者

name:Alcon Laboratories
url:http://www.alcon.com
name:Apotex Inc.
url:http://www.apotex.com
name:Dispensing Solutions
url:http://www.drxdispensing.com
name:Falcon Pharmaceuticals Ltd.
url:http://www.falconpharma.com
name:GD Searle LLC
url:
name:Golden State Medical Supply Inc.
url:http://www.gsms.us
name:Kaiser Foundation Hospital
url:
name:KVK-Tech Inc.
url:http://www.kvktech.com
name:Murfreesboro Pharmaceutical Nursing Supply
url:http://www.unitdosesupply.com
name:Novex Pharma
url:
name:Pharmedix
url:http://www.pharmedixrx.com
name:Physicians Total Care Inc.
url:http://www.physicianstotalcare.com
name:Sanofi-Aventis Inc.
url:http://www.sanofi-aventis.com

生产者

generic:是; url:; name;Akorn inc
generic:是; url:; name;Bausch and lomb pharmaceuticals inc
generic:是; url:; name;Novex pharma
generic:是; url:; name;Wockhardt ltd
generic:否; url:; name;Alcon laboratories inc
generic:是; url:; name;Epic pharma llc
generic:是; url:; name;Kvk tech inc
generic:否; url:; name;Sanofi aventis us llc
generic:否; url:; name;Alcon inc

价格

Betaxolol 10 mg tablet
1.24(单位：USD）
tablet
Betaxolol HCl 10 mg tablet
1.29(单位：USD）
tablet
Kerlone 10 mg tablet
1.63(单位：USD）
tablet
Betaxolol 20 mg tablet
1.86(单位：USD）
tablet
Kerlone 20 mg tablet
2.35(单位：USD）
tablet
Betoptic S 0.25 % Suspension
2.54(单位：USD）
ml
Betaxolol hcl 0.5% eye drop
6.82(单位：USD）
ml
Betoptic s 0.25% eye drops
9.79(单位：USD）
ml
Betoptic-S 0.25% Suspension 5ml Bottle
51.99(单位：USD）
bottle
Betaxolol HCl 0.5% Solution 15ml Bottle
104.31(单位：USD）
bottle
Betoptic-S 0.25% Suspension 10ml Bottle
130.29(单位：USD）
bottle
Betoptic-S 0.25% Suspension 15ml Bottle
195.44(单位：USD）
bottle

受影响的生物体

Humans and other mammals

剂量

form:Solution / drops
route:Ophthalmic
strength:5 mg/1mL
form:Tablet, film coated
route:Oral
strength:10 mg/1
form:Tablet, coated
route:Oral
strength:10 mg/1
form:Tablet, coated
route:Oral
strength:20 mg/1
form:Solution / drops
route:Ophthalmic
strength:0.25 %
form:Solution / drops
route:Ophthalmic
strength:2.5 mg
form:Solution / drops
route:Ophthalmic
strength:5 MG/ML
form:Solution / drops
route:Ophthalmic
strength:5.6 mg/1mL
form:Liquid
route:Ophthalmic
strength:
form:Kit
route:Ophthalmic
strength:
form:Solution / drops
route:Ophthalmic
strength:250 mg/100mL
form:Suspension / drops
route:Ophthalmic
strength:2.8 mg/1mL
form:Suspension
route:Ophthalmic
strength:2.8 mg/ml
form:Suspension
route:Ophthalmic
strength:0.25 %
form:Suspension
route:Ophthalmic
strength:
form:Solution / drops
route:Ophthalmic
strength:5.6 mg/ml
form:Solution / drops; suspension / drops
route:Ophthalmic
strength:5 mg/mL
form:Solution / drops
route:Ophthalmic
strength:0.5 %
form:Solution / drops
route:Ophthalmic
strength:0.5 % W/V
form:Tablet, coated
route:Oral
strength:20 mg
form:Tablet, film coated
route:Oral
strength:20 mg/1
form:Tablet, film coated
route:Oral
strength:20 MG
form:Solution / drops
route:Ophthalmic
strength:
form:Solution
route:Ophthalmic
strength:

atc代码

Beta blocking agents
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
OPHTHALMOLOGICALS
SENSORY ORGANS
Beta blocking agents, selective
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
CARDIOVASCULAR SYSTEM
Beta blocking agents
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
OPHTHALMOLOGICALS
SENSORY ORGANS

fda标签

//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00195.pdf?1265922797

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00195.pdf?1265922737

专利

number:5540918
country:United States
approved:1996-07-30
expires:2014-01-30
pediatric-extension:否

食物相互作用

No food interactions are expected.

药物相互作用

DB00476
The risk or severity of orthostatic hypotension and syncope can be increased when Betaxolol is combined with Duloxetine.
DB01235
The risk or severity of hypotension and orthostatic hypotension can be increased when Betaxolol is combined with Levodopa.
DB00734
Betaxolol may increase the hypotensive activities of Risperidone.
DB09063
Betaxolol may increase the bradycardic activities of Ceritinib.
DB09083
Betaxolol may increase the bradycardic activities of Ivabradine.
DB08877
Ruxolitinib may increase the bradycardic activities of Betaxolol.
DB01609
The serum concentration of Betaxolol can be increased when it is combined with Deferasirox.
DB00022
The serum concentration of Betaxolol can be increased when it is combined with Peginterferon alfa-2b.
DB01097
The serum concentration of Betaxolol can be decreased when it is combined with Leflunomide.
DB08880
The serum concentration of Betaxolol can be decreased when it is combined with Teriflunomide.
DB00346
Alfuzosin may increase the hypotensive activities of Betaxolol.
DB01143
Betaxolol may increase the hypotensive activities of Amifostine.
DB01119
Diazoxide may increase the hypotensive activities of Betaxolol.
DB00422
Methylphenidate may decrease the antihypertensive activities of Betaxolol.
DB06701
Dexmethylphenidate may decrease the antihypertensive activities of Betaxolol.
DB08935
Betaxolol may increase the hypotensive activities of Obinutuzumab.
DB00806
Pentoxifylline may increase the hypotensive activities of Betaxolol.
DB00073
Betaxolol may increase the hypotensive activities of Rituximab.
DB00035
Desmopressin may decrease the antihypertensive activities of Betaxolol.
DB00561
Doxapram may decrease the antihypertensive activities of Betaxolol.
DB00669
Sumatriptan may decrease the antihypertensive activities of Betaxolol.
DB00830
Phenmetrazine may decrease the antihypertensive activities of Betaxolol.
DB00952
Naratriptan may decrease the antihypertensive activities of Betaxolol.
DB00953
Rizatriptan may decrease the antihypertensive activities of Betaxolol.
DB00988
Dopamine may decrease the antihypertensive activities of Betaxolol.
DB01126
Dutasteride may decrease the antihypertensive activities of Betaxolol.
DB01216
Finasteride may decrease the antihypertensive activities of Betaxolol.
DB01392
Yohimbine may decrease the antihypertensive activities of Betaxolol.
DB02032
Epicaptopril may decrease the antihypertensive activities of Betaxolol.
DB04581
1-benzylimidazole may decrease the antihypertensive activities of Betaxolol.
DB04836
Amineptine may decrease the antihypertensive activities of Betaxolol.
DB04908
Flibanserin may decrease the antihypertensive activities of Betaxolol.
DB05562
Naluzotan may decrease the antihypertensive activities of Betaxolol.
DB06690
Nitrous oxide may decrease the antihypertensive activities of Betaxolol.
DB08810
Cinitapride may decrease the antihypertensive activities of Betaxolol.
DB08841
Tyramine may decrease the antihypertensive activities of Betaxolol.
DB08954
Ifenprodil may decrease the antihypertensive activities of Betaxolol.
DB08996
Dimetacrine may decrease the antihypertensive activities of Betaxolol.
DB09205
Moxisylyte may decrease the antihypertensive activities of Betaxolol.
DB09289
Tianeptine may decrease the antihypertensive activities of Betaxolol.
DB09307
Oxaprotiline may decrease the antihypertensive activities of Betaxolol.
DB11481
Atipamezole may decrease the antihypertensive activities of Betaxolol.
DB11755
Tetrahydrocannabivarin may decrease the antihypertensive activities of Betaxolol.
DB12361
Piclozotan may decrease the antihypertensive activities of Betaxolol.
DB12371
Siponimod may decrease the antihypertensive activities of Betaxolol.
DB12551
Idazoxan may decrease the antihypertensive activities of Betaxolol.
DB13064
Tramazoline may decrease the antihypertensive activities of Betaxolol.
DB13114
Amitriptylinoxide may decrease the antihypertensive activities of Betaxolol.
DB13225
Dibenzepin may decrease the antihypertensive activities of Betaxolol.
DB13246
Quinupramine may decrease the antihypertensive activities of Betaxolol.
DB13323
Trichloroethylene may decrease the antihypertensive activities of Betaxolol.
DB13341
Fenozolone may decrease the antihypertensive activities of Betaxolol.
DB13384
Melitracen may decrease the antihypertensive activities of Betaxolol.
DB13411
Lofepramine may decrease the antihypertensive activities of Betaxolol.
DB13453
Xenon may decrease the antihypertensive activities of Betaxolol.
DB13496
Iprindole may decrease the antihypertensive activities of Betaxolol.
DB13510
Buflomedil may decrease the antihypertensive activities of Betaxolol.
DB13598
Diethyl ether may decrease the antihypertensive activities of Betaxolol.
DB13782
Imipramine oxide may decrease the antihypertensive activities of Betaxolol.
DB13852
Mefenorex may decrease the antihypertensive activities of Betaxolol.
DB14010
5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Betaxolol.
DB14231
Quinoline Yellow WS may decrease the antihypertensive activities of Betaxolol.
DB14754
Solriamfetol may decrease the antihypertensive activities of Betaxolol.
DB00708
Sufentanil may decrease the antihypertensive activities of Betaxolol.
DB00899
Remifentanil may decrease the antihypertensive activities of Betaxolol.
DB01159
Halothane may decrease the antihypertensive activities of Betaxolol.
DB12930
Opipramol may decrease the antihypertensive activities of Betaxolol.
DB15685
Selpercatinib may decrease the antihypertensive activities of Betaxolol.
DB15965
Naxitamab may decrease the antihypertensive activities of Betaxolol.
DB01118
The therapeutic efficacy of Betaxolol can be increased when used in combination with Amiodarone.
DB00297
The serum concentration of Bupivacaine can be increased when it is combined with Betaxolol.
DB00975
Dipyridamole may increase the bradycardic activities of Betaxolol.
DB00280
Disopyramide may increase the bradycardic activities of Betaxolol.
DB04855
Dronedarone may increase the bradycardic activities of Betaxolol.
DB08868
Betaxolol may increase the bradycardic activities of Fingolimod.
DB08976
The risk or severity of adverse effects can be increased when Betaxolol is combined with Floctafenine.
DB00961
The serum concentration of Mepivacaine can be increased when it is combined with Betaxolol.
DB06709
Betaxolol may increase the bronchoconstrictory activities of Methacholine.
DB00211
The therapeutic efficacy of Midodrine can be decreased when used in combination with Betaxolol.
DB01115
The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Betaxolol.
DB01182
The risk or severity of adverse effects can be increased when Propafenone is combined with Betaxolol.
DB08896
Regorafenib may increase the bradycardic activities of Betaxolol.
DB00206
Reserpine may increase the hypotensive activities of Betaxolol.
DB01089
Deserpidine may increase the hypotensive activities of Betaxolol.
DB01170
Guanethidine may increase the hypotensive activities of Betaxolol.
DB00989
Betaxolol may increase the bradycardic activities of Rivastigmine.
DB05812
The serum concentration of Betaxolol can be increased when it is combined with Abiraterone.
DB09220
Nicorandil may increase the hypotensive activities of Betaxolol.
DB09282
Molsidomine may increase the hypotensive activities of Betaxolol.
DB11564
Betaxolol may increase the hypoglycemic activities of Insulin argine.
DB04839
The metabolism of Betaxolol can be increased when combined with Cyproterone acetate.
DB00287
Betaxolol may increase the hypotensive activities of Travoprost.
DB00869
Betaxolol may increase the hypotensive activities of Dorzolamide.
DB00905
Betaxolol may increase the hypotensive activities of Bimatoprost.
DB06826
Betaxolol may increase the hypotensive activities of Unoprostone.
DB00212
Betaxolol may increase the hypotensive activities of Remikiren.
DB00214
Betaxolol may increase the hypotensive activities of Torasemide.
DB00226
Betaxolol may increase the hypotensive activities of Guanadrel.
DB00310
Betaxolol may increase the hypotensive activities of Chlorthalidone.
DB00325
Betaxolol may increase the hypotensive activities of Nitroprusside.
DB00350
Betaxolol may increase the hypotensive activities of Minoxidil.
DB00524
Betaxolol may increase the hypotensive activities of Metolazone.
DB00559
Betaxolol may increase the hypotensive activities of Bosentan.
DB00616
Betaxolol may increase the hypotensive activities of Candoxatril.
DB00657
Betaxolol may increase the hypotensive activities of Mecamylamine.
DB00727
Betaxolol may increase the hypotensive activities of Nitroglycerin.
DB00765
Betaxolol may increase the hypotensive activities of Metyrosine.
DB00785
Betaxolol may increase the hypotensive activities of Cryptenamine.
DB00800
Betaxolol may increase the hypotensive activities of Fenoldopam.
DB01090
Betaxolol may increase the hypotensive activities of Pentolinium.
DB01116
Betaxolol may increase the hypotensive activities of Trimethaphan.
DB01275
Betaxolol may increase the hypotensive activities of Hydralazine.
DB04831
Betaxolol may increase the hypotensive activities of Tienilic acid.
DB04840
Betaxolol may increase the hypotensive activities of Debrisoquine.
DB06268
Betaxolol may increase the hypotensive activities of Sitaxentan.
DB06403
Betaxolol may increase the hypotensive activities of Ambrisentan.
DB06445
Betaxolol may increase the hypotensive activities of Diethylnorspermine.
DB06762
Betaxolol may increase the hypotensive activities of Pinacidil.
DB07767
Betaxolol may increase the hypotensive activities of Ferulic acid.
DB08931
Betaxolol may increase the hypotensive activities of Riociguat.
DB08932
Betaxolol may increase the hypotensive activities of Macitentan.
DB08960
Betaxolol may increase the hypotensive activities of Hexamethonium.
DB09363
Betaxolol may increase the hypotensive activities of Rauwolfia serpentina root.
DB11362
Betaxolol may increase the hypotensive activities of Selexipag.
DB11720
Betaxolol may increase the hypotensive activities of Angiotensin 1-7.
DB12054
Betaxolol may increase the hypotensive activities of BQ-123.
DB12465
Betaxolol may increase the hypotensive activities of Ketanserin.
DB13211
Betaxolol may increase the hypotensive activities of Guanoxan.
DB13374
Betaxolol may increase the hypotensive activities of Vincamine.
DB13400
Betaxolol may increase the hypotensive activities of Linsidomine.
DB13410
Betaxolol may increase the hypotensive activities of Guanoxabenz.
DB13429
Betaxolol may increase the hypotensive activities of Tolonidine.
DB13435
Betaxolol may increase the hypotensive activities of Endralazine.
DB13452
Betaxolol may increase the hypotensive activities of Cadralazine.
DB13575
Betaxolol may increase the hypotensive activities of Bietaserpine.
DB13604
Betaxolol may increase the hypotensive activities of Guanazodine.
DB13631
Betaxolol may increase the hypotensive activities of Methoserpidine.
DB13779
Betaxolol may increase the hypotensive activities of Guanoclor.
DB13801
Betaxolol may increase the hypotensive activities of Muzolimine.
DB13803
Betaxolol may increase the hypotensive activities of Xipamide.
DB14094
Betaxolol may increase the hypotensive activities of Tocopherylquinone.
DB00695
Furosemide may increase the hypotensive activities of Betaxolol.
DB00178
Ramipril may increase the hypotensive activities of Betaxolol.
DB00790
Betaxolol may increase the hypotensive activities of Perindopril.
DB09237
Betaxolol may increase the hypotensive activities of Levamlodipine.
DB00484
Brimonidine may increase the antihypertensive activities of Betaxolol.
DB00185
The risk or severity of adverse effects can be increased when Betaxolol is combined with Cevimeline.
DB00411
The risk or severity of adverse effects can be increased when Betaxolol is combined with Carbamoylcholine.
DB01019
The risk or severity of adverse effects can be increased when Betaxolol is combined with Bethanechol.
DB01085
The risk or severity of adverse effects can be increased when Betaxolol is combined with Pilocarpine.
DB01273
The risk or severity of adverse effects can be increased when Betaxolol is combined with Varenicline.
DB03128
The risk or severity of adverse effects can be increased when Betaxolol is combined with Acetylcholine.
DB04365
The risk or severity of adverse effects can be increased when Betaxolol is combined with Arecoline.
DB05137
The risk or severity of adverse effects can be increased when Betaxolol is combined with Lobeline.
DB05152
The risk or severity of adverse effects can be increased when Betaxolol is combined with NGX267.
DB07720
The risk or severity of adverse effects can be increased when Betaxolol is combined with Epibatidine.
DB15357
The risk or severity of adverse effects can be increased when Betaxolol is combined with Xanomeline.
DB00372
The serum concentration of Betaxolol can be increased when it is combined with Thiethylperazine.
DB00420
The serum concentration of Betaxolol can be increased when it is combined with Promazine.
DB00433
The serum concentration of Betaxolol can be increased when it is combined with Prochlorperazine.
DB00508
The serum concentration of Betaxolol can be increased when it is combined with Triflupromazine.
DB00623
The serum concentration of Betaxolol can be increased when it is combined with Fluphenazine.
DB00831
The serum concentration of Betaxolol can be increased when it is combined with Trifluoperazine.
DB00850
The serum concentration of Betaxolol can be increased when it is combined with Perphenazine.
DB00933
The serum concentration of Betaxolol can be increased when it is combined with Mesoridazine.
DB01063
The serum concentration of Betaxolol can be increased when it is combined with Acetophenazine.
DB01069
The serum concentration of Betaxolol can be increased when it is combined with Promethazine.
DB01246
The serum concentration of Betaxolol can be increased when it is combined with Alimemazine.
DB01608
The serum concentration of Betaxolol can be increased when it is combined with Periciazine.
DB01614
The serum concentration of Betaxolol can be increased when it is combined with Acepromazine.
DB01615
The serum concentration of Betaxolol can be increased when it is combined with Aceprometazine.
DB01621
The serum concentration of Betaxolol can be increased when it is combined with Pipotiazine.
DB01622
The serum concentration of Betaxolol can be increased when it is combined with Thioproperazine.
DB05687
The serum concentration of Betaxolol can be increased when it is combined with BL-1020.
DB09000
The serum concentration of Betaxolol can be increased when it is combined with Cyamemazine.
DB09241
The serum concentration of Betaxolol can be increased when it is combined with Methylene blue.
DB11540
The serum concentration of Betaxolol can be increased when it is combined with Propiopromazine.
DB12710
The serum concentration of Betaxolol can be increased when it is combined with Perazine.
DB13213
The serum concentration of Betaxolol can be increased when it is combined with Butaperazine.
DB13382
The serum concentration of Betaxolol can be increased when it is combined with Chlorproethazine.
DB13420
The serum concentration of Betaxolol can be increased when it is combined with Thiazinam.
DB13784
The serum concentration of Betaxolol can be increased when it is combined with Dixyrazine.
DB14651
The serum concentration of Betaxolol can be increased when it is combined with Perphenazine enanthate.
DB01092
Betaxolol may increase the bradycardic activities of Ouabain.
DB12843
Betaxolol may increase the bradycardic activities of Oleandrin.
DB13307
Betaxolol may increase the bradycardic activities of Proscillaridin.
DB13467
Betaxolol may increase the bradycardic activities of Lanatoside C.
DB13537
Betaxolol may increase the bradycardic activities of Gitoformate.
DB13756
Betaxolol may increase the bradycardic activities of Peruvoside.
DB00281
The serum concentration of Lidocaine can be increased when it is combined with Betaxolol.
DB00159
Icosapent may decrease the antihypertensive activities of Betaxolol.
DB00244
Mesalazine may decrease the antihypertensive activities of Betaxolol.
DB00328
Indomethacin may decrease the antihypertensive activities of Betaxolol.
DB00461
Nabumetone may decrease the antihypertensive activities of Betaxolol.
DB00465
Ketorolac may decrease the antihypertensive activities of Betaxolol.
DB00469
Tenoxicam may decrease the antihypertensive activities of Betaxolol.
DB00482
Celecoxib may decrease the antihypertensive activities of Betaxolol.
DB00500
Tolmetin may decrease the antihypertensive activities of Betaxolol.
DB00533
Rofecoxib may decrease the antihypertensive activities of Betaxolol.
DB00554
Piroxicam may decrease the antihypertensive activities of Betaxolol.
DB00573
Fenoprofen may decrease the antihypertensive activities of Betaxolol.
DB00580
Valdecoxib may decrease the antihypertensive activities of Betaxolol.
DB00586
Diclofenac may decrease the antihypertensive activities of Betaxolol.
DB00605
Sulindac may decrease the antihypertensive activities of Betaxolol.
DB00712
Flurbiprofen may decrease the antihypertensive activities of Betaxolol.
DB00749
Etodolac may decrease the antihypertensive activities of Betaxolol.
DB00784
Mefenamic acid may decrease the antihypertensive activities of Betaxolol.
DB00788
Naproxen may decrease the antihypertensive activities of Betaxolol.
DB00795
Sulfasalazine may decrease the antihypertensive activities of Betaxolol.
DB00812
Phenylbutazone may decrease the antihypertensive activities of Betaxolol.
DB00814
Meloxicam may decrease the antihypertensive activities of Betaxolol.
DB00821
Carprofen may decrease the antihypertensive activities of Betaxolol.
DB00861
Diflunisal may decrease the antihypertensive activities of Betaxolol.
DB00936
Salicylic acid may decrease the antihypertensive activities of Betaxolol.
DB00939
Meclofenamic acid may decrease the antihypertensive activities of Betaxolol.
DB00945
Acetylsalicylic acid may decrease the antihypertensive activities of Betaxolol.
DB00991
Oxaprozin may decrease the antihypertensive activities of Betaxolol.
DB01009
Ketoprofen may decrease the antihypertensive activities of Betaxolol.
DB01014
Balsalazide may decrease the antihypertensive activities of Betaxolol.
DB01050
Ibuprofen may decrease the antihypertensive activities of Betaxolol.
DB01250
Olsalazine may decrease the antihypertensive activities of Betaxolol.
DB01283
Lumiracoxib may decrease the antihypertensive activities of Betaxolol.
DB01397
Magnesium salicylate may decrease the antihypertensive activities of Betaxolol.
DB01399
Salsalate may decrease the antihypertensive activities of Betaxolol.
DB01401
Choline magnesium trisalicylate may decrease the antihypertensive activities of Betaxolol.
DB01419
Antrafenine may decrease the antihypertensive activities of Betaxolol.
DB01424
Aminophenazone may decrease the antihypertensive activities of Betaxolol.
DB01435
Antipyrine may decrease the antihypertensive activities of Betaxolol.
DB01600
Tiaprofenic acid may decrease the antihypertensive activities of Betaxolol.
DB01628
Etoricoxib may decrease the antihypertensive activities of Betaxolol.
DB02224
Taxifolin may decrease the antihypertensive activities of Betaxolol.
DB03585
Oxyphenbutazone may decrease the antihypertensive activities of Betaxolol.
DB04725
Licofelone may decrease the antihypertensive activities of Betaxolol.
DB04743
Nimesulide may decrease the antihypertensive activities of Betaxolol.
DB04812
Benoxaprofen may decrease the antihypertensive activities of Betaxolol.
DB04817
Metamizole may decrease the antihypertensive activities of Betaxolol.
DB04828
Zomepirac may decrease the antihypertensive activities of Betaxolol.
DB05095
Cimicoxib may decrease the antihypertensive activities of Betaxolol.
DB06725
Lornoxicam may decrease the antihypertensive activities of Betaxolol.
DB06736
Aceclofenac may decrease the antihypertensive activities of Betaxolol.
DB06737
Zaltoprofen may decrease the antihypertensive activities of Betaxolol.
DB07402
Azapropazone may decrease the antihypertensive activities of Betaxolol.
DB08439
Parecoxib may decrease the antihypertensive activities of Betaxolol.
DB08797
Salicylamide may decrease the antihypertensive activities of Betaxolol.
DB08940
Kebuzone may decrease the antihypertensive activities of Betaxolol.
DB08942
Isoxicam may decrease the antihypertensive activities of Betaxolol.
DB08951
Indoprofen may decrease the antihypertensive activities of Betaxolol.
DB08955
Ibuproxam may decrease the antihypertensive activities of Betaxolol.
DB08981
Fenbufen may decrease the antihypertensive activities of Betaxolol.
DB08984
Etofenamate may decrease the antihypertensive activities of Betaxolol.
DB08991
Epirizole may decrease the antihypertensive activities of Betaxolol.
DB09084
Benzydamine may decrease the antihypertensive activities of Betaxolol.
DB09213
Dexibuprofen may decrease the antihypertensive activities of Betaxolol.
DB09214
Dexketoprofen may decrease the antihypertensive activities of Betaxolol.
DB09215
Droxicam may decrease the antihypertensive activities of Betaxolol.
DB09216
Tolfenamic acid may decrease the antihypertensive activities of Betaxolol.
DB09217
Firocoxib may decrease the antihypertensive activities of Betaxolol.
DB09218
Clonixin may decrease the antihypertensive activities of Betaxolol.
DB09285
Morniflumate may decrease the antihypertensive activities of Betaxolol.
DB09288
Propacetamol may decrease the antihypertensive activities of Betaxolol.
DB09295
Talniflumate may decrease the antihypertensive activities of Betaxolol.
DB11455
Robenacoxib may decrease the antihypertensive activities of Betaxolol.
DB11466
Tepoxalin may decrease the antihypertensive activities of Betaxolol.
DB11518
Flunixin may decrease the antihypertensive activities of Betaxolol.
DB12399
Polmacoxib may decrease the antihypertensive activities of Betaxolol.
DB12445
Nitroaspirin may decrease the antihypertensive activities of Betaxolol.
DB12545
Indobufen may decrease the antihypertensive activities of Betaxolol.
DB12610
Ebselen may decrease the antihypertensive activities of Betaxolol.
DB13001
Tinoridine may decrease the antihypertensive activities of Betaxolol.
DB13167
Alclofenac may decrease the antihypertensive activities of Betaxolol.
DB13217
Fentiazac may decrease the antihypertensive activities of Betaxolol.
DB13232
Suxibuzone may decrease the antihypertensive activities of Betaxolol.
DB13286
Bumadizone may decrease the antihypertensive activities of Betaxolol.
DB13314
Alminoprofen may decrease the antihypertensive activities of Betaxolol.
DB13371
Difenpiramide may decrease the antihypertensive activities of Betaxolol.
DB13407
Nifenazone may decrease the antihypertensive activities of Betaxolol.
DB13432
Lonazolac may decrease the antihypertensive activities of Betaxolol.
DB13481
Tenidap may decrease the antihypertensive activities of Betaxolol.
DB13524
Propyphenazone may decrease the antihypertensive activities of Betaxolol.
DB13527
Proglumetacin may decrease the antihypertensive activities of Betaxolol.
DB13538
Guacetisal may decrease the antihypertensive activities of Betaxolol.
DB13544
Ethenzamide may decrease the antihypertensive activities of Betaxolol.
DB13612
Carbaspirin calcium may decrease the antihypertensive activities of Betaxolol.
DB13629
Mofebutazone may decrease the antihypertensive activities of Betaxolol.
DB13649
Proquazone may decrease the antihypertensive activities of Betaxolol.
DB13657
Benorilate may decrease the antihypertensive activities of Betaxolol.
DB13722
Pirprofen may decrease the antihypertensive activities of Betaxolol.
DB13783
Acemetacin may decrease the antihypertensive activities of Betaxolol.
DB13860
Imidazole salicylate may decrease the antihypertensive activities of Betaxolol.
DB14059
SC-236 may decrease the antihypertensive activities of Betaxolol.
DB14060
NS-398 may decrease the antihypertensive activities of Betaxolol.
DB14938
Flurbiprofen axetil may decrease the antihypertensive activities of Betaxolol.
DB09212
Loxoprofen may decrease the antihypertensive activities of Betaxolol.
DB00203
Sildenafil may increase the antihypertensive activities of Betaxolol.
DB00235
Milrinone may increase the antihypertensive activities of Betaxolol.
DB00820
Tadalafil may increase the antihypertensive activities of Betaxolol.
DB05266
Ibudilast may increase the antihypertensive activities of Betaxolol.
DB06237
Avanafil may increase the antihypertensive activities of Betaxolol.
DB06267
Udenafil may increase the antihypertensive activities of Betaxolol.
DB11792
Mirodenafil may increase the antihypertensive activities of Betaxolol.
DB12010
Fostamatinib may increase the antihypertensive activities of Betaxolol.
DB00247
Betaxolol may increase the vasoconstricting activities of Methysergide.
DB00248
Betaxolol may increase the vasoconstricting activities of Cabergoline.
DB00320
Betaxolol may increase the vasoconstricting activities of Dihydroergotamine.
DB00353
Betaxolol may increase the vasoconstricting activities of Methylergometrine.
DB00589
Betaxolol may increase the vasoconstricting activities of Lisuride.
DB00696
Betaxolol may increase the vasoconstricting activities of Ergotamine.
DB00699
Betaxolol may increase the vasoconstricting activities of Nicergoline.
DB01049
Betaxolol may increase the vasoconstricting activities of Ergoloid mesylate.
DB04829
Betaxolol may increase the vasoconstricting activities of Lysergic acid diethylamide.
DB11273
Betaxolol may increase the vasoconstricting activities of Dihydroergocornine.
DB13345
Betaxolol may increase the vasoconstricting activities of Dihydroergocristine.
DB13385
Betaxolol may increase the vasoconstricting activities of Dihydroergocryptine.
DB13399
Betaxolol may increase the vasoconstricting activities of Terguride.
DB13520
Betaxolol may increase the vasoconstricting activities of Metergoline.
DB01105
The serum concentration of Betaxolol can be increased when it is combined with Sibutramine.
DB01149
The serum concentration of Betaxolol can be increased when it is combined with Nefazodone.
DB04832
The serum concentration of Betaxolol can be increased when it is combined with Zimelidine.
DB04884
The serum concentration of Betaxolol can be increased when it is combined with Dapoxetine.
DB04896
The serum concentration of Betaxolol can be increased when it is combined with Milnacipran.
DB06700
The serum concentration of Betaxolol can be increased when it is combined with Desvenlafaxine.
DB06731
The serum concentration of Betaxolol can be increased when it is combined with Seproxetine.
DB08918
The serum concentration of Betaxolol can be increased when it is combined with Levomilnacipran.
DB08953
The serum concentration of Betaxolol can be increased when it is combined with Indalpine.
DB13233
The serum concentration of Betaxolol can be increased when it is combined with Alaproclate.
DB01104
The serum concentration of Betaxolol can be increased when it is combined with Sertraline.
DB00201
The risk or severity of adverse effects can be increased when Betaxolol is combined with Caffeine.
DB00651
The risk or severity of adverse effects can be increased when Betaxolol is combined with Dyphylline.
DB01223
The risk or severity of adverse effects can be increased when Betaxolol is combined with Aminophylline.
DB01303
The risk or severity of adverse effects can be increased when Betaxolol is combined with Oxtriphylline.
DB01412
The risk or severity of adverse effects can be increased when Betaxolol is combined with Theobromine.
DB01482
The risk or severity of adverse effects can be increased when Betaxolol is combined with Fenethylline.
DB01667
The risk or severity of adverse effects can be increased when Betaxolol is combined with 8-azaguanine.
DB01978
The risk or severity of adverse effects can be increased when Betaxolol is combined with 7,9-Dimethylguanine.
DB02134
The risk or severity of adverse effects can be increased when Betaxolol is combined with Xanthine.
DB02245
The risk or severity of adverse effects can be increased when Betaxolol is combined with 7-Deazaguanine.
DB02377
The risk or severity of adverse effects can be increased when Betaxolol is combined with Guanine.
DB02489
The risk or severity of adverse effects can be increased when Betaxolol is combined with 9-Methylguanine.
DB02568
The risk or severity of adverse effects can be increased when Betaxolol is combined with Peldesine.
DB04076
The risk or severity of adverse effects can be increased when Betaxolol is combined with Hypoxanthine.
DB04356
The risk or severity of adverse effects can be increased when Betaxolol is combined with 9-Deazaguanine.
DB06479
The risk or severity of adverse effects can be increased when Betaxolol is combined with Propentofylline.
DB06575
The risk or severity of adverse effects can be increased when Betaxolol is combined with Valomaciclovir.
DB07954
The risk or severity of adverse effects can be increased when Betaxolol is combined with 3-isobutyl-1-methyl-7H-xanthine.
DB08844
The risk or severity of adverse effects can be increased when Betaxolol is combined with Uric acid.
DB11919
The risk or severity of adverse effects can be increased when Betaxolol is combined with 6-O-benzylguanine.
DB12406
The risk or severity of adverse effects can be increased when Betaxolol is combined with Lisofylline.
DB12531
The risk or severity of adverse effects can be increased when Betaxolol is combined with Lobucavir.
DB12926
The risk or severity of adverse effects can be increased when Betaxolol is combined with Cafedrine.
DB12927
The risk or severity of adverse effects can be increased when Betaxolol is combined with Theodrenaline.
DB13203
The risk or severity of adverse effects can be increased when Betaxolol is combined with Bamifylline.
DB13449
The risk or severity of adverse effects can be increased when Betaxolol is combined with Proxyphylline.
DB13573
The risk or severity of adverse effects can be increased when Betaxolol is combined with Acefylline.
DB13592
The risk or severity of adverse effects can be increased when Betaxolol is combined with Etamiphylline.
DB13634
The risk or severity of adverse effects can be increased when Betaxolol is combined with Pentifylline.
DB13812
The risk or severity of adverse effects can be increased when Betaxolol is combined with Bufylline.
DB14018
The risk or severity of adverse effects can be increased when Betaxolol is combined with Bromotheophylline.
DB14132
The risk or severity of adverse effects can be increased when Betaxolol is combined with 8-chlorotheophylline.
DB00521
Betaxolol may increase the arrhythmogenic activities of Carteolol.
DB01214
Betaxolol may increase the arrhythmogenic activities of Metipranolol.
DB00680
Moricizine may increase the arrhythmogenic activities of Betaxolol.
DB00390
Betaxolol may increase the arrhythmogenic activities of Digoxin.
DB00511
Betaxolol may increase the arrhythmogenic activities of Acetyldigitoxin.
DB01078
Betaxolol may increase the arrhythmogenic activities of Deslanoside.
DB01396
Betaxolol may increase the arrhythmogenic activities of Digitoxin.
DB13240
Betaxolol may increase the arrhythmogenic activities of Cymarin.
DB13401
Betaxolol may increase the arrhythmogenic activities of Metildigoxin.
DB13691
Betaxolol may increase the arrhythmogenic activities of Acetyldigoxin.
DB00222
Betaxolol may increase the arrhythmogenic activities of Glimepiride.
DB11699
Betaxolol may increase the arrhythmogenic activities of Tropisetron.
DB12704
Betaxolol may increase the arrhythmogenic activities of Spiradoline.
DB13635
Betaxolol may increase the arrhythmogenic activities of Tiracizine.
DB13645
Betaxolol may increase the arrhythmogenic activities of Ethacizine.
DB13718
Betaxolol may increase the arrhythmogenic activities of Hydroquinine.
DB13746
Betaxolol may increase the arrhythmogenic activities of Bioallethrin.
DB13863
Betaxolol may increase the arrhythmogenic activities of Fosfructose.
DB15300
Betaxolol may increase the arrhythmogenic activities of Hydroquinidine.
DB15366
SOR-C13 may increase the arrhythmogenic activities of Betaxolol.
DB00204
Betaxolol may increase the arrhythmogenic activities of Dofetilide.
DB00308
Betaxolol may increase the arrhythmogenic activities of Ibutilide.
DB00908
Betaxolol may increase the arrhythmogenic activities of Quinidine.
DB00571
Betaxolol may increase the arrhythmogenic activities of Propranolol.
DB00572
Betaxolol may increase the arrhythmogenic activities of Atropine.
DB00640
Betaxolol may increase the arrhythmogenic activities of Adenosine.
DB00922
Betaxolol may increase the arrhythmogenic activities of Levosimendan.
DB01193
Betaxolol may increase the arrhythmogenic activities of Acebutolol.
DB01580
Betaxolol may increase the arrhythmogenic activities of Oxprenolol.
DB04957
Betaxolol may increase the arrhythmogenic activities of Azimilide.
DB06200
Betaxolol may increase the arrhythmogenic activities of Tedisamil.
DB09224
Betaxolol may increase the arrhythmogenic activities of Melperone.
DB12286
Betaxolol may increase the arrhythmogenic activities of Simendan.
DB13546
Betaxolol may increase the arrhythmogenic activities of Nizofenone.
DB13652
Betaxolol may increase the arrhythmogenic activities of Bunaftine.
DB13653
Betaxolol may increase the arrhythmogenic activities of Lorcainide.
DB00187
Esmolol may increase the arrhythmogenic activities of Betaxolol.
DB00230
Pregabalin may increase the arrhythmogenic activities of Betaxolol.
DB00424
Hyoscyamine may increase the arrhythmogenic activities of Betaxolol.
DB00678
Losartan may increase the arrhythmogenic activities of Betaxolol.
DB00825
Levomenthol may increase the arrhythmogenic activities of Betaxolol.
DB01158
Bretylium may increase the arrhythmogenic activities of Betaxolol.
DB01228
Encainide may increase the arrhythmogenic activities of Betaxolol.
DB01426
Ajmaline may increase the arrhythmogenic activities of Betaxolol.
DB06217
Vernakalant may increase the arrhythmogenic activities of Betaxolol.
DB06468
Cariporide may increase the arrhythmogenic activities of Betaxolol.
DB08808
Bupranolol may increase the arrhythmogenic activities of Betaxolol.
DB08952
Indenolol may increase the arrhythmogenic activities of Betaxolol.
DB11770
Talinolol may increase the arrhythmogenic activities of Betaxolol.
DB12712
Pilsicainide may increase the arrhythmogenic activities of Betaxolol.
DB12766
Cicletanine may increase the arrhythmogenic activities of Betaxolol.
DB13358
Cibenzoline may increase the arrhythmogenic activities of Betaxolol.
DB13555
Prajmaline may increase the arrhythmogenic activities of Betaxolol.
DB13651
Lorajmine may increase the arrhythmogenic activities of Betaxolol.
DB00335
Betaxolol may increase the arrhythmogenic activities of Atenolol.
DB00866
Betaxolol may increase the arrhythmogenic activities of Alprenolol.
DB01203
Betaxolol may increase the arrhythmogenic activities of Nadolol.
DB01297
Betaxolol may increase the arrhythmogenic activities of Practolol.
DB12212
Betaxolol may increase the arrhythmogenic activities of Landiolol.
DB13775
Betaxolol may increase the arrhythmogenic activities of Tertatolol.
DB14207
Betaxolol may increase the arrhythmogenic activities of Fosinoprilat.
DB04846
Betaxolol may increase the arrhythmogenic activities of Celiprolol.
DB04861
Betaxolol may increase the arrhythmogenic activities of Nebivolol.
DB11785
Betaxolol may increase the arrhythmogenic activities of Anisodamine.
DB03322
Betaxolol may increase the arrhythmogenic activities of Dexpropranolol.
DB00379
Mexiletine may increase the arrhythmogenic activities of Betaxolol.
DB06727
Sparteine may increase the arrhythmogenic activities of Betaxolol.
DB01429
Betaxolol may increase the arrhythmogenic activities of Aprindine.
DB00489
Betaxolol may increase the arrhythmogenic activities of Sotalol.
DB01035
Betaxolol may increase the arrhythmogenic activities of Procainamide.
DB01195
Betaxolol may increase the arrhythmogenic activities of Flecainide.
DB01056
Betaxolol may increase the arrhythmogenic activities of Tocainide.
DB00401
The risk or severity of bradycardia can be increased when Nisoldipine is combined with Betaxolol.
DB00653
The risk or severity of bradycardia can be increased when Magnesium sulfate is combined with Betaxolol.
DB04838
The risk or severity of bradycardia can be increased when Cyclandelate is combined with Betaxolol.
DB04841
The risk or severity of bradycardia can be increased when Flunarizine is combined with Betaxolol.
DB04920
The risk or severity of bradycardia can be increased when Clevidipine is combined with Betaxolol.
DB05885
The risk or severity of bradycardia can be increased when Seletracetam is combined with Betaxolol.
DB06446
The risk or severity of bradycardia can be increased when Dotarizine is combined with Betaxolol.
DB07615
The risk or severity of bradycardia can be increased when Tranilast is combined with Betaxolol.
DB08162
The risk or severity of bradycardia can be increased when Fasudil is combined with Betaxolol.
DB08838
The risk or severity of bradycardia can be increased when Agmatine is combined with Betaxolol.
DB09230
The risk or severity of bradycardia can be increased when Azelnidipine is combined with Betaxolol.
DB09232
The risk or severity of bradycardia can be increased when Cilnidipine is combined with Betaxolol.
DB09234
The risk or severity of bradycardia can be increased when Darodipine is combined with Betaxolol.
DB09240
The risk or severity of bradycardia can be increased when Niludipine is combined with Betaxolol.
DB11960
The risk or severity of bradycardia can be increased when Carboxyamidotriazole is combined with Betaxolol.
DB12092
The risk or severity of bradycardia can be increased when Naftopidil is combined with Betaxolol.
DB12131
The risk or severity of bradycardia can be increased when Vinpocetine is combined with Betaxolol.
DB13835
The risk or severity of bradycardia can be increased when Caroverine is combined with Betaxolol.
DB13950
The risk or severity of bradycardia can be increased when WIN 55212-2 is combined with Betaxolol.
DB13961
The risk or severity of bradycardia can be increased when Fish oil is combined with Betaxolol.
DB14064
The risk or severity of bradycardia can be increased when Emopamil is combined with Betaxolol.
DB14065
The risk or severity of bradycardia can be increased when Lomerizine is combined with Betaxolol.
DB14066
The risk or severity of bradycardia can be increased when Tetrandrine is combined with Betaxolol.
DB14068
The risk or severity of bradycardia can be increased when Dexniguldipine is combined with Betaxolol.
DB01136
The risk or severity of bradycardia can be increased when Betaxolol is combined with Carvedilol.
DB09239
The risk or severity of bradycardia can be increased when Betaxolol is combined with Niguldipine.
DB01244
The risk or severity of bradycardia can be increased when Betaxolol is combined with Bepridil.
DB13725
The risk or severity of bradycardia can be increased when Betaxolol is combined with Terodiline.
DB00343
The risk or severity of bradycardia can be increased when Betaxolol is combined with Diltiazem.
DB00393
The risk or severity of bradycardia can be increased when Betaxolol is combined with Nimodipine.
DB00568
The risk or severity of bradycardia can be increased when Betaxolol is combined with Cinnarizine.
DB00836
The risk or severity of bradycardia can be increased when Betaxolol is combined with Loperamide.
DB01388
The risk or severity of bradycardia can be increased when Betaxolol is combined with Mibefradil.
DB04825
The risk or severity of bradycardia can be increased when Betaxolol is combined with Prenylamine.
DB04842
The risk or severity of bradycardia can be increased when Betaxolol is combined with Fluspirilene.
DB06712
The risk or severity of bradycardia can be increased when Betaxolol is combined with Nilvadipine.
DB08980
The risk or severity of bradycardia can be increased when Betaxolol is combined with Fendiline.
DB08992
The risk or severity of bradycardia can be increased when Betaxolol is combined with Eperisone.
DB09231
The risk or severity of bradycardia can be increased when Betaxolol is combined with Benidipine.
DB13500
The risk or severity of bradycardia can be increased when Betaxolol is combined with Otilonium.
DB13791
The risk or severity of bradycardia can be increased when Betaxolol is combined with Penfluridol.
DB14063
The risk or severity of bradycardia can be increased when Betaxolol is combined with Dexverapamil.
DB00270
The risk or severity of bradycardia can be increased when Isradipine is combined with Betaxolol.
DB00347
The risk or severity of bradycardia can be increased when Trimethadione is combined with Betaxolol.
DB00381
The risk or severity of bradycardia can be increased when Amlodipine is combined with Betaxolol.
DB00555
The risk or severity of bradycardia can be increased when Lamotrigine is combined with Betaxolol.
DB00593
The risk or severity of bradycardia can be increased when Ethosuximide is combined with Betaxolol.
DB00909
The risk or severity of bradycardia can be increased when Zonisamide is combined with Betaxolol.
DB01023
The risk or severity of bradycardia can be increased when Felodipine is combined with Betaxolol.
DB01054
The risk or severity of bradycardia can be increased when Nitrendipine is combined with Betaxolol.
DB05246
The risk or severity of bradycardia can be increased when Methsuximide is combined with Betaxolol.
DB06283
The risk or severity of bradycardia can be increased when Ziconotide is combined with Betaxolol.
DB09089
The risk or severity of bradycardia can be increased when Trimebutine is combined with Betaxolol.
DB09090
The risk or severity of bradycardia can be increased when Pinaverium is combined with Betaxolol.
DB09229
The risk or severity of bradycardia can be increased when Aranidipine is combined with Betaxolol.
DB09235
The risk or severity of bradycardia can be increased when Efonidipine is combined with Betaxolol.
DB12093
The risk or severity of bradycardia can be increased when Tetrahydropalmatine is combined with Betaxolol.
DB12923
The risk or severity of bradycardia can be increased when Gallopamil is combined with Betaxolol.
DB13488
The risk or severity of bradycardia can be increased when Bencyclane is combined with Betaxolol.
DB13766
The risk or severity of bradycardia can be increased when Lidoflazine is combined with Betaxolol.
DB06152
The risk or severity of bradycardia can be increased when Betaxolol is combined with Nylidrin.
DB06694
The risk or severity of bradycardia can be increased when Betaxolol is combined with Xylometazoline.
DB00528
The risk or severity of bradycardia can be increased when Betaxolol is combined with Lercanidipine.
DB00590
Betaxolol may increase the orthostatic hypotensive activities of Doxazosin.
DB00598
Betaxolol may increase the orthostatic hypotensive activities of Labetalol.
DB00692
Betaxolol may increase the orthostatic hypotensive activities of Phentolamine.
DB00706
Betaxolol may increase the orthostatic hypotensive activities of Tamsulosin.
DB00777
Betaxolol may increase the orthostatic hypotensive activities of Propiomazine.
DB00797
Betaxolol may increase the orthostatic hypotensive activities of Tolazoline.
DB00925
Betaxolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.
DB01162
Betaxolol may increase the orthostatic hypotensive activities of Terazosin.
DB01295
Betaxolol may increase the orthostatic hypotensive activities of Bevantolol.
DB06153
Betaxolol may increase the orthostatic hypotensive activities of Pizotifen.
DB06207
Betaxolol may increase the orthostatic hypotensive activities of Silodosin.
DB08950
Betaxolol may increase the orthostatic hypotensive activities of Indoramin.
DB09128
Betaxolol may increase the orthostatic hypotensive activities of Brexpiprazole.
DB09206
Betaxolol may increase the orthostatic hypotensive activities of Trimazosin.
DB12230
Betaxolol may increase the orthostatic hypotensive activities of Bunazosin.
DB12278
Betaxolol may increase the orthostatic hypotensive activities of Propiverine.
DB12661
Betaxolol may increase the orthostatic hypotensive activities of Urapidil.
DB12752
Betaxolol may increase the orthostatic hypotensive activities of Bucindolol.
DB00374
Treprostinil may increase the hypotensive activities of Betaxolol.
DB01088
Iloprost may increase the hypotensive activities of Betaxolol.
DB01240
Epoprostenol may increase the hypotensive activities of Betaxolol.
DB14337
Salvia miltiorrhiza root may increase the hypotensive activities of Betaxolol.
DB00082
Pegvisomant may increase the bradycardic activities of Betaxolol.
DB00392
Profenamine may increase the bradycardic activities of Betaxolol.
DB00483
Gallamine triethiodide may increase the bradycardic activities of Betaxolol.
DB00515
Cisplatin may increase the bradycardic activities of Betaxolol.
DB00527
Cinchocaine may increase the bradycardic activities of Betaxolol.
DB00545
Pyridostigmine may increase the bradycardic activities of Betaxolol.
DB00585
Nizatidine may increase the bradycardic activities of Betaxolol.
DB00677
Isoflurophate may increase the bradycardic activities of Betaxolol.
DB00711
Diethylcarbamazine may increase the bradycardic activities of Betaxolol.
DB00888
Mechlorethamine may increase the bradycardic activities of Betaxolol.
DB00941
Hexafluronium may increase the bradycardic activities of Betaxolol.
DB00944
Demecarium may increase the bradycardic activities of Betaxolol.
DB00981
Physostigmine may increase the bradycardic activities of Betaxolol.
DB01010
Edrophonium may increase the bradycardic activities of Betaxolol.
DB01043
Memantine may increase the bradycardic activities of Betaxolol.
DB01122
Ambenonium may increase the bradycardic activities of Betaxolol.
DB01199
Tubocurarine may increase the bradycardic activities of Betaxolol.
DB01221
Ketamine may increase the bradycardic activities of Betaxolol.
DB01245
Decamethonium may increase the bradycardic activities of Betaxolol.
DB01337
Pancuronium may increase the bradycardic activities of Betaxolol.
DB01338
Pipecuronium may increase the bradycardic activities of Betaxolol.
DB01381
Ginkgo biloba may increase the bradycardic activities of Betaxolol.
DB01400
Neostigmine may increase the bradycardic activities of Betaxolol.
DB02365
1,10-Phenanthroline may increase the bradycardic activities of Betaxolol.
DB04572
Thiotepa may increase the bradycardic activities of Betaxolol.
DB04864
Huperzine A may increase the bradycardic activities of Betaxolol.
DB04892
Phenserine may increase the bradycardic activities of Betaxolol.
DB05386
Regramostim may increase the bradycardic activities of Betaxolol.
DB06692
Aprotinin may increase the bradycardic activities of Betaxolol.
DB06756
Glycine betaine may increase the bradycardic activities of Betaxolol.
DB11473
Metrifonate may increase the bradycardic activities of Betaxolol.
DB12482
Acotiamide may increase the bradycardic activities of Betaxolol.
DB13058
Methanesulfonyl Fluoride may increase the bradycardic activities of Betaxolol.
DB13495
Paraoxon may increase the bradycardic activities of Betaxolol.
DB13503
Tyrothricin may increase the bradycardic activities of Betaxolol.
DB13668
Ipidacrine may increase the bradycardic activities of Betaxolol.
DB13694
Distigmine may increase the bradycardic activities of Betaxolol.
DB14031
Tretamine may increase the bradycardic activities of Betaxolol.
DB15317
Posiphen may increase the bradycardic activities of Betaxolol.
DB00843
Betaxolol may increase the bradycardic activities of Donepezil.
DB02845
Methylphosphinic Acid may increase the bradycardic activities of Betaxolol.
DB00601
Linezolid may increase the hypotensive activities of Betaxolol.
DB00614
Furazolidone may increase the hypotensive activities of Betaxolol.
DB00721
Procaine may increase the hypotensive activities of Betaxolol.
DB00780
Phenelzine may increase the hypotensive activities of Betaxolol.
DB00805
Minaprine may increase the hypotensive activities of Betaxolol.
DB01037
Selegiline may increase the hypotensive activities of Betaxolol.
DB01168
Procarbazine may increase the hypotensive activities of Betaxolol.
DB01171
Moclobemide may increase the hypotensive activities of Betaxolol.
DB01247
Isocarboxazid may increase the hypotensive activities of Betaxolol.
DB01367
Rasagiline may increase the hypotensive activities of Betaxolol.
DB01626
Pargyline may increase the hypotensive activities of Betaxolol.
DB04017
Clorgiline may increase the hypotensive activities of Betaxolol.
DB04818
Iproniazid may increase the hypotensive activities of Betaxolol.
DB04820
Nialamide may increase the hypotensive activities of Betaxolol.
DB06654
Safinamide may increase the hypotensive activities of Betaxolol.
DB08550
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Betaxolol.
DB09243
Hydracarbazine may increase the hypotensive activities of Betaxolol.
DB09244
Pirlindole may increase the hypotensive activities of Betaxolol.
DB09245
Toloxatone may increase the hypotensive activities of Betaxolol.
DB09246
Benmoxin may increase the hypotensive activities of Betaxolol.
DB09248
Mebanazine may increase the hypotensive activities of Betaxolol.
DB09249
Octamoxin may increase the hypotensive activities of Betaxolol.
DB09250
Pheniprazine may increase the hypotensive activities of Betaxolol.
DB09251
Phenoxypropazine may increase the hypotensive activities of Betaxolol.
DB09252
Pivhydrazine may increase the hypotensive activities of Betaxolol.
DB09253
Safrazine may increase the hypotensive activities of Betaxolol.
DB09254
Caroxazone may increase the hypotensive activities of Betaxolol.
DB13875
Harmaline may increase the hypotensive activities of Betaxolol.
DB13876
Brofaromine may increase the hypotensive activities of Betaxolol.
DB01174
Phenobarbital may increase the hypotensive activities of Betaxolol.
DB00237
Butabarbital may increase the hypotensive activities of Betaxolol.
DB00241
The serum concentration of Betaxolol can be decreased when it is combined with Butalbital.
DB00312
The serum concentration of Betaxolol can be decreased when it is combined with Pentobarbital.
DB00418
The serum concentration of Betaxolol can be decreased when it is combined with Secobarbital.
DB00474
The serum concentration of Betaxolol can be decreased when it is combined with Methohexital.
DB00599
The serum concentration of Betaxolol can be decreased when it is combined with Thiopental.
DB00849
The serum concentration of Betaxolol can be decreased when it is combined with Methylphenobarbital.
DB01154
The serum concentration of Betaxolol can be decreased when it is combined with Thiamylal.
DB01351
The serum concentration of Betaxolol can be decreased when it is combined with Amobarbital.
DB01355
The serum concentration of Betaxolol can be decreased when it is combined with Hexobarbital.
DB01483
The serum concentration of Betaxolol can be decreased when it is combined with Barbital.
DB09001
The serum concentration of Betaxolol can be decreased when it is combined with Barbexaclone.
DB00215
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Citalopram.
DB00261
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Anagrelide.
DB00283
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Clemastine.
DB00313
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Valproic acid.
DB00365
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Grepafloxacin.
DB00539
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Toremifene.
DB00619
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Imatinib.
DB00685
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Trovafloxacin.
DB00875
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Flupentixol.
DB00907
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Cocaine.
DB01169
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Arsenic trioxide.
DB01184
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Domperidone.
DB01208
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Sparfloxacin.
DB01267
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Paliperidone.
DB01356
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Lithium cation.
DB01405
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Temafloxacin.
DB01624
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Zuclopenthixol.
DB04844
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Tetrabenazine.
DB04946
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Iloperidone.
DB05294
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Vandetanib.
DB06176
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Romidepsin.
DB06216
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Asenapine.
DB06697
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Artemether.
DB09039
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Eliglustat.
DB11730
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Ribociclib.
DB11978
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Glasdegib.
DB12161
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Deutetrabenazine.
DB13074
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Macimorelin.
DB00007
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Betaxolol.
DB00014
The risk or severity of QTc prolongation can be increased when Goserelin is combined with Betaxolol.
DB00199
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Erythromycin.
DB00207
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Azithromycin.
DB00391
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Sulpiride.
DB00450
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Droperidol.
DB00526
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Oxaliplatin.
DB00544
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Fluorouracil.
DB00556
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Perflutren.
DB00625
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Efavirenz.
DB00743
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Gadobenic acid.
DB00748
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Carbinoxamine.
DB00757
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Dolasetron.
DB00778
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Roxithromycin.
DB00779
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Nalidixic acid.
DB00827
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Cinoxacin.
DB00889
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Granisetron.
DB00904
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Ondansetron.
DB00967
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Desloratadine.
DB00976
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Telithromycin.
DB00978
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Lomefloxacin.
DB00985
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Dimenhydrinate.
DB01113
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Papaverine.
DB01114
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Chlorpheniramine.
DB01137
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Levofloxacin.
DB01155
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Gemifloxacin.
DB01165
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Ofloxacin.
DB01211
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Clarithromycin.
DB01227
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Levacetylmethadol.
DB01232
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Saquinavir.
DB01599
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Probucol.
DB02638
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Terlipressin.
DB05223
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Pracinostat.
DB06160
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Garenoxacin.
DB06334
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Tucidinostat.
DB06402
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Telavancin.
DB06589
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Pazopanib.
DB06600
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Nemonoxacin.
DB08799
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Antazoline.
DB08865
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Crizotinib.
DB08903
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Bedaquiline.
DB09016
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Butriptyline.
DB09078
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Lenvatinib.
DB09555
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Dexchlorpheniramine maleate.
DB11640
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Amifampridine.
DB11830
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Mocetinostat.
DB11841
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Entinostat.
DB12141
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Gilteritinib.
DB12174
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with CUDC-101.
DB12376
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Ricolinostat.
DB12523
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Mizolastine.
DB12565
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Abexinostat.
DB12877
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Oxatomide.
DB13261
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Sitafloxacin.
DB13273
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Sultopride.
DB13679
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Dexchlorpheniramine.
DB14568
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Ivosidenib.
DB01084
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Emedastine.
DB11718
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Encorafenib.
DB00862
The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Betaxolol.
DB00107
The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Betaxolol.
DB00196
The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Betaxolol.
DB00245
The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Betaxolol.
DB00289
The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Betaxolol.
DB00334
The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Betaxolol.
DB00341
The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Betaxolol.
DB00354
The risk or severity of QTc prolongation can be increased when Buclizine is combined with Betaxolol.
DB00366
The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Betaxolol.
DB00370
The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Betaxolol.
DB00398
The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Betaxolol.
DB00405
The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Betaxolol.
DB00427
The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Betaxolol.
DB00434
The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Betaxolol.
DB00487
The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Betaxolol.
DB00529
The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Betaxolol.
DB00582
The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Betaxolol.
DB00674
The risk or severity of QTc prolongation can be increased when Galantamine is combined with Betaxolol.
DB00691
The risk or severity of QTc prolongation can be increased when Moexipril is combined with Betaxolol.
DB00710
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Betaxolol.
DB00714
The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Betaxolol.
DB00719
The risk or severity of QTc prolongation can be increased when Azatadine is combined with Betaxolol.
DB00753
The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Betaxolol.
DB00817
The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Betaxolol.
DB00818
The risk or severity of QTc prolongation can be increased when Propofol is combined with Betaxolol.
DB00822
The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Betaxolol.
DB00835
The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Betaxolol.
DB00915
The risk or severity of QTc prolongation can be increased when Amantadine is combined with Betaxolol.
DB00916
The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Betaxolol.
DB00920
The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Betaxolol.
DB00927
The risk or severity of QTc prolongation can be increased when Famotidine is combined with Betaxolol.
DB00934
The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Betaxolol.
DB00949
The risk or severity of QTc prolongation can be increased when Felbamate is combined with Betaxolol.
DB01036
The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Betaxolol.
DB01059
The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Betaxolol.
DB01071
The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Betaxolol.
DB01072
The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Betaxolol.
DB01106
The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Betaxolol.
DB01166
The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Betaxolol.
DB01176
The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Betaxolol.
DB01189
The risk or severity of QTc prolongation can be increased when Desflurane is combined with Betaxolol.
DB01236
The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Betaxolol.
DB01239
The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Betaxolol.
DB01254
The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Betaxolol.
DB01259
The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Betaxolol.
DB01263
The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Betaxolol.
DB01591
The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Betaxolol.
DB01620
The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Betaxolol.
DB02546
The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Betaxolol.
DB04576
The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Betaxolol.
DB04695
The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Betaxolol.
DB04953
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Betaxolol.
DB05465
The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Betaxolol.
DB06282
The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Betaxolol.
DB06288
The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Betaxolol.
DB06663
The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Betaxolol.
DB06699
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Betaxolol.
DB06719
The risk or severity of QTc prolongation can be increased when Buserelin is combined with Betaxolol.
DB06788
The risk or severity of QTc prolongation can be increased when Histrelin is combined with Betaxolol.
DB06825
The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Betaxolol.
DB07780
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Betaxolol.
DB07841
The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Betaxolol.
DB08815
The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Betaxolol.
DB08864
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Betaxolol.
DB08871
The risk or severity of QTc prolongation can be increased when Eribulin is combined with Betaxolol.
DB08912
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Betaxolol.
DB08936
The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Betaxolol.
DB08972
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Betaxolol.
DB09488
The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Betaxolol.
DB11390
The risk or severity of QTc prolongation can be increased when Coumaphos is combined with Betaxolol.
DB11397
The risk or severity of QTc prolongation can be increased when Dichlorvos is combined with Betaxolol.
DB11408
The risk or severity of QTc prolongation can be increased when Famphur is combined with Betaxolol.
DB11412
The risk or severity of QTc prolongation can be increased when Fenthion is combined with Betaxolol.
DB11443
The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Betaxolol.
DB11448
The risk or severity of QTc prolongation can be increased when Phosmet is combined with Betaxolol.
DB11491
The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Betaxolol.
DB11511
The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Betaxolol.
DB11591
The risk or severity of QTc prolongation can be increased when Bilastine is combined with Betaxolol.
DB11614
The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Betaxolol.
DB11742
The risk or severity of QTc prolongation can be increased when Ebastine is combined with Betaxolol.
DB11891
The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Betaxolol.
DB11892
The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Betaxolol.
DB11943
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Betaxolol.
DB12231
The risk or severity of QTc prolongation can be increased when Temefos is combined with Betaxolol.
DB12245
The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Betaxolol.
DB12645
The risk or severity of QTc prolongation can be increased when Givinostat is combined with Betaxolol.
DB13627
The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Betaxolol.
DB13744
The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Betaxolol.
DB13772
The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Betaxolol.
DB13823
The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Betaxolol.
DB14713
The risk or severity of QTc prolongation can be increased when Inotersen is combined with Betaxolol.
DB00864
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Tacrolimus.
DB01167
The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Betaxolol.
DB01601
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Betaxolol.
DB00344
The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Betaxolol.
DB00845
The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Betaxolol.
DB11796
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Betaxolol.
DB00751
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Epinastine.
DB11853
The risk or severity of QTc prolongation can be increased when Relugolix is combined with Betaxolol.
DB00041
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Betaxolol.
DB00086
The risk or severity of adverse effects can be increased when Streptokinase is combined with Betaxolol.
DB00268
The risk or severity of adverse effects can be increased when Ropinirole is combined with Betaxolol.
DB00295
The risk or severity of adverse effects can be increased when Morphine is combined with Betaxolol.
DB00323
The risk or severity of adverse effects can be increased when Tolcapone is combined with Betaxolol.
DB00413
The risk or severity of adverse effects can be increased when Pramipexole is combined with Betaxolol.
DB00486
The risk or severity of adverse effects can be increased when Nabilone is combined with Betaxolol.
DB00631
The risk or severity of adverse effects can be increased when Clofarabine is combined with Betaxolol.
DB00681
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Betaxolol.
DB00755
The risk or severity of adverse effects can be increased when Tretinoin is combined with Betaxolol.
DB00872
The risk or severity of adverse effects can be increased when Conivaptan is combined with Betaxolol.
DB00883
The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Betaxolol.
DB00887
The risk or severity of adverse effects can be increased when Bumetanide is combined with Betaxolol.
DB00903
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Betaxolol.
DB01020
The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Betaxolol.
DB01041
The risk or severity of adverse effects can be increased when Thalidomide is combined with Betaxolol.
DB01144
The risk or severity of adverse effects can be increased when Diclofenamide is combined with Betaxolol.
DB01229
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Betaxolol.
DB01282
The risk or severity of adverse effects can be increased when Carbetocin is combined with Betaxolol.
DB01612
The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Betaxolol.
DB04899
The risk or severity of adverse effects can be increased when Nesiritide is combined with Betaxolol.
DB09077
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Betaxolol.
DB09112
The risk or severity of adverse effects can be increased when Nitrous acid is combined with Betaxolol.
DB09286
The risk or severity of adverse effects can be increased when Pipamperone is combined with Betaxolol.
DB09292
The risk or severity of adverse effects can be increased when Sacubitril is combined with Betaxolol.
DB00703
The risk or severity of adverse effects can be increased when Methazolamide is combined with Betaxolol.
DB00802
Betaxolol may increase the bradycardic activities of Alfentanil.
DB00813
Betaxolol may increase the bradycardic activities of Fentanyl.
DB04897
Betaxolol may increase the bradycardic activities of Lucinactant.
DB06218
Betaxolol may increase the bradycardic activities of Lacosamide.
DB06415
Betaxolol may increase the bradycardic activities of Calfactant.
DB06761
Betaxolol may increase the bradycardic activities of Beractant.
DB06791
Betaxolol may increase the bradycardic activities of Lanreotide.
DB08895
Betaxolol may increase the bradycardic activities of Tofacitinib.
DB09113
Betaxolol may increase the bradycardic activities of Poractant alfa.
DB00564
The metabolism of Betaxolol can be increased when combined with Carbamazepine.
DB00794
The metabolism of Betaxolol can be increased when combined with Primidone.
DB00218
The metabolism of Betaxolol can be decreased when combined with Moxifloxacin.
DB00969
The metabolism of Betaxolol can be decreased when combined with Alosetron.
DB01044
The metabolism of Betaxolol can be decreased when combined with Gatifloxacin.
DB06290
The metabolism of Betaxolol can be decreased when combined with Simeprevir.
DB11774
The metabolism of Betaxolol can be decreased when combined with Pazufloxacin.
DB11837
The metabolism of Betaxolol can be decreased when combined with Osilodrostat.
DB00477
The metabolism of Betaxolol can be decreased when combined with Chlorpromazine.
DB12693
The metabolism of Betaxolol can be decreased when combined with Ritanserin.
DB00622
The metabolism of Nicardipine can be decreased when combined with Betaxolol.
DB00752
The metabolism of Betaxolol can be decreased when combined with Tranylcypromine.
DB00342
The metabolism of Terfenadine can be decreased when combined with Betaxolol.
DB00468
The metabolism of Quinine can be decreased when combined with Betaxolol.
DB04868
The metabolism of Nilotinib can be decreased when combined with Betaxolol.
DB06708
The metabolism of Lumefantrine can be decreased when combined with Betaxolol.
DB00363
The metabolism of Clozapine can be decreased when combined with Betaxolol.
DB00285
The metabolism of Betaxolol can be decreased when combined with Venlafaxine.
DB00608
The metabolism of Betaxolol can be decreased when combined with Chloroquine.
DB01087
The metabolism of Betaxolol can be decreased when combined with Primaquine.
DB08893
The metabolism of Mirabegron can be decreased when combined with Betaxolol.
DB01026
The metabolism of Betaxolol can be decreased when combined with Ketoconazole.
DB00091
The metabolism of Betaxolol can be decreased when combined with Cyclosporine.
DB00169
The metabolism of Betaxolol can be decreased when combined with Cholecalciferol.
DB00264
The metabolism of Betaxolol can be decreased when combined with Metoprolol.
DB00349
The metabolism of Betaxolol can be decreased when combined with Clobazam.
DB00496
The metabolism of Betaxolol can be decreased when combined with Darifenacin.
DB00501
The metabolism of Betaxolol can be decreased when combined with Cimetidine.
DB00705
The metabolism of Betaxolol can be decreased when combined with Delavirdine.
DB00932
The metabolism of Betaxolol can be decreased when combined with Tipranavir.
DB01074
The metabolism of Betaxolol can be decreased when combined with Perhexiline.
DB02703
The metabolism of Betaxolol can be decreased when combined with Fusidic acid.
DB06603
The metabolism of Betaxolol can be decreased when combined with Panobinostat.
DB06684
The metabolism of Betaxolol can be decreased when combined with Vilazodone.
DB06729
The metabolism of Betaxolol can be decreased when combined with Sulfaphenazole.
DB06819
The metabolism of Betaxolol can be decreased when combined with Phenylbutyric acid.
DB09238
The metabolism of Betaxolol can be decreased when combined with Manidipine.
DB09291
The metabolism of Betaxolol can be decreased when combined with Rolapitant.
DB11586
The metabolism of Betaxolol can be decreased when combined with Asunaprevir.
DB00458
The metabolism of Imipramine can be decreased when combined with Betaxolol.
DB01151
The metabolism of Desipramine can be decreased when combined with Betaxolol.
DB09167
The metabolism of Dosulepin can be decreased when combined with Betaxolol.
DB00503
The metabolism of Betaxolol can be decreased when combined with Ritonavir.
DB01079
The metabolism of Betaxolol can be decreased when combined with Tegaserod.
DB13174
The metabolism of Betaxolol can be decreased when combined with Rhein.
DB00857
The metabolism of Terbinafine can be decreased when combined with Betaxolol.
DB12332
The metabolism of Rucaparib can be decreased when combined with Betaxolol.
DB00176
The metabolism of Betaxolol can be decreased when combined with Fluvoxamine.
DB04871
The metabolism of Lorcaserin can be decreased when combined with Betaxolol.
DB15982
The metabolism of Betaxolol can be decreased when combined with Berotralstat.
DB00604
The metabolism of Betaxolol can be decreased when combined with Cisapride.
DB00679
The metabolism of Betaxolol can be decreased when combined with Thioridazine.
DB00715
The metabolism of Betaxolol can be decreased when combined with Paroxetine.
DB01012
The metabolism of Betaxolol can be decreased when combined with Cinacalcet.
DB01156
The metabolism of Betaxolol can be decreased when combined with Bupropion.
DB01173
The metabolism of Betaxolol can be decreased when combined with Orphenadrine.
DB01218
The metabolism of Betaxolol can be decreased when combined with Halofantrine.
DB01403
The metabolism of Betaxolol can be decreased when combined with Methotrimeprazine.
DB08909
The metabolism of Betaxolol can be decreased when combined with Glycerol phenylbutyrate.
DB00358
The risk or severity of QTc prolongation can be decreased when Mefloquine is combined with Betaxolol.
DB00613
The risk or severity of QTc prolongation can be decreased when Amodiaquine is combined with Betaxolol.
DB01611
The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Betaxolol.
DB01033
The therapeutic efficacy of Mercaptopurine can be decreased when used in combination with Betaxolol.
DB15122
The therapeutic efficacy of PCS-499 can be decreased when used in combination with Betaxolol.
DB00177
The risk or severity of hyperkalemia can be increased when Valsartan is combined with Betaxolol.
DB00202
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Succinylcholine.
DB00275
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Olmesartan.
DB00407
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Ardeparin.
DB00421
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Spironolactone.
DB00492
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Fosinopril.
DB00519
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Trandolapril.
DB00542
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Benazepril.
DB00584
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Enalapril.
DB00594
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Amiloride.
DB00698
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Nitrofurantoin.
DB00700
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Eplerenone.
DB00722
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Lisinopril.
DB00742
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Mannitol.
DB00796
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Candesartan cilexetil.
DB00876
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Eprosartan.
DB00881
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Quinapril.
DB00886
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Omapatrilat.
DB00960
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Pindolol.
DB00966
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Telmisartan.
DB01029
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Irbesartan.
DB01109
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Heparin.
DB01180
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Rescinnamine.
DB01197
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Captopril.
DB01219
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Dantrolene.
DB01225
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Enoxaparin.
DB01340
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Cilazapril.
DB01342
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Forasartan.
DB01347
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Saprisartan.
DB01348
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Spirapril.
DB01349
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Tasosartan.
DB01359
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Penbutolol.
DB01395
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Drospirenone.
DB02968
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Penicillin G Acyl-Serine.
DB06212
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Tolvaptan.
DB06271
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Sulodexide.
DB06726
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Bufuralol.
DB06754
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Danaparoid.
DB06763
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Saralasin.
DB06767
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Ammonium chloride.
DB06779
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Dalteparin.
DB06822
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Tinzaparin.
DB08807
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Bopindolol.
DB08813
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Nadroparin.
DB08822
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Azilsartan medoxomil.
DB08836
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Temocapril.
DB09015
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Canrenoic acid.
DB09026
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Aliskiren.
DB09204
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Arotinolol.
DB09258
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Bemiparin.
DB09259
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Reviparin.
DB09260
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Parnaparin.
DB09261
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Certoparin.
DB09279
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Fimasartan.
DB09351
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Levobetaxolol.
DB09477
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Enalaprilat.
DB11783
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Imidapril.
DB12097
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Mannitol busulfan.
DB12221
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Canrenone.
DB13166
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Zofenopril.
DB13312
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Delapril.
DB13443
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Esatenolol.
DB13508
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Cloranolol.
DB13530
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Mepindolol.
DB13757
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Epanolol.
DB13919
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Candesartan.
DB14125
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Benazeprilat.
DB14208
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Ramiprilat.
DB14213
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Perindoprilat.
DB14217
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Quinaprilat.
DB00440
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Trimethoprim.
DB09330
The serum concentration of Betaxolol can be decreased when it is combined with Osimertinib.
DB10349
The risk of a hypersensitivity reaction to Paspalum notatum pollen is increased when it is combined with Betaxolol.
DB10351
The risk of a hypersensitivity reaction to Cynodon dactylon pollen is increased when it is combined with Betaxolol.
DB10353
The risk of a hypersensitivity reaction to Poa annua pollen is increased when it is combined with Betaxolol.
DB10365
The risk of a hypersensitivity reaction to Sorghum halepense pollen is increased when it is combined with Betaxolol.
DB10366
The risk of a hypersensitivity reaction to Poa pratensis pollen is increased when it is combined with Betaxolol.
DB10370
The risk of a hypersensitivity reaction to Festuca pratensis pollen is increased when it is combined with Betaxolol.
DB10379
The risk of a hypersensitivity reaction to Dactylis glomerata pollen is increased when it is combined with Betaxolol.
DB10389
The risk of a hypersensitivity reaction to Lolium perenne pollen is increased when it is combined with Betaxolol.
DB10394
The risk of a hypersensitivity reaction to Phleum pratense pollen is increased when it is combined with Betaxolol.
DB10395
The risk of a hypersensitivity reaction to Holcus lanatus pollen is increased when it is combined with Betaxolol.
DB10403
The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Betaxolol.
DB10404
The risk of a hypersensitivity reaction to Anthoxanthum odoratum pollen is increased when it is combined with Betaxolol.
DB10489
The risk of a hypersensitivity reaction to Elymus repens pollen is increased when it is combined with Betaxolol.
DB10494
The risk of a hypersensitivity reaction to Distichlis spicata pollen is increased when it is combined with Betaxolol.
DB10713
The risk of a hypersensitivity reaction to Poa compressa pollen is increased when it is combined with Betaxolol.
DB10714
The risk of a hypersensitivity reaction to Phalaris arundinacea pollen is increased when it is combined with Betaxolol.
DB10715
The risk of a hypersensitivity reaction to Bouteloua gracilis pollen is increased when it is combined with Betaxolol.
DB10716
The risk of a hypersensitivity reaction to Urochloa mutica pollen is increased when it is combined with Betaxolol.
DB10717
The risk of a hypersensitivity reaction to Secale cereale pollen is increased when it is combined with Betaxolol.
DB10719
The risk of a hypersensitivity reaction to Pascopyrum smithii pollen is increased when it is combined with Betaxolol.
DB10836
The risk of a hypersensitivity reaction to Bromus secalinus pollen is increased when it is combined with Betaxolol.
DB10879
The risk of a hypersensitivity reaction to Arrhenatherum elatius pollen is increased when it is combined with Betaxolol.
DB10949
The risk of a hypersensitivity reaction to Koeleria macrantha pollen is increased when it is combined with Betaxolol.
DB10962
The risk of a hypersensitivity reaction to Agrostis stolonifera pollen is increased when it is combined with Betaxolol.
DB10963
The risk of a hypersensitivity reaction to Phalaris minor pollen is increased when it is combined with Betaxolol.
DB10964
The risk of a hypersensitivity reaction to Lolium perenne subsp. multiflorum pollen is increased when it is combined with Betaxolol.
DB10966
The risk of a hypersensitivity reaction to Sorghum bicolor subsp. drummondii pollen is increased when it is combined with Betaxolol.
DB01045
The metabolism of Betaxolol can be increased when combined with Rifampicin.
DB01201
The metabolism of Betaxolol can be increased when combined with Rifapentine.
DB01220
The metabolism of Betaxolol can be increased when combined with Rifaximin.
DB11753
The metabolism of Betaxolol can be increased when combined with Rifamycin.
DB15213
The metabolism of Betaxolol can be increased when combined with 25-desacetylrifapentine.
DB08881
The serum concentration of Betaxolol can be increased when it is combined with Vemurafenib.
DB09236
Betaxolol may increase the hypotensive activities of Lacidipine.
DB00898
Ethanol may increase the hypotensive activities of Betaxolol.
DB09227
Betaxolol may increase the antihypertensive activities of Barnidipine.
DB11637
Betaxolol may increase the QTc-prolonging activities of Delamanid.
DB13967
The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Betaxolol.
DB00217
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Betaxolol.
DB00221
The therapeutic efficacy of Isoetharine can be decreased when used in combination with Betaxolol.
DB00292
The therapeutic efficacy of Etomidate can be decreased when used in combination with Betaxolol.
DB00368
The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Betaxolol.
DB00388
The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Betaxolol.
DB00397
The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Betaxolol.
DB00610
The therapeutic efficacy of Metaraminol can be decreased when used in combination with Betaxolol.
DB00629
The therapeutic efficacy of Guanabenz can be decreased when used in combination with Betaxolol.
DB00633
The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Betaxolol.
DB00668
The therapeutic efficacy of Epinephrine can be decreased when used in combination with Betaxolol.
DB00697
The therapeutic efficacy of Tizanidine can be decreased when used in combination with Betaxolol.
DB00723
The therapeutic efficacy of Methoxamine can be decreased when used in combination with Betaxolol.
DB00816
The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Betaxolol.
DB00841
The therapeutic efficacy of Dobutamine can be decreased when used in combination with Betaxolol.
DB00867
The therapeutic efficacy of Ritodrine can be decreased when used in combination with Betaxolol.
DB00871
The therapeutic efficacy of Terbutaline can be decreased when used in combination with Betaxolol.
DB00901
The therapeutic efficacy of Bitolterol can be decreased when used in combination with Betaxolol.
DB00935
The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Betaxolol.
DB00938
The therapeutic efficacy of Salmeterol can be decreased when used in combination with Betaxolol.
DB00968
The therapeutic efficacy of Methyldopa can be decreased when used in combination with Betaxolol.
DB00983
The therapeutic efficacy of Formoterol can be decreased when used in combination with Betaxolol.
DB01001
The therapeutic efficacy of Salbutamol can be decreased when used in combination with Betaxolol.
DB01018
The therapeutic efficacy of Guanfacine can be decreased when used in combination with Betaxolol.
DB01064
The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Betaxolol.
DB01102
The therapeutic efficacy of Arbutamine can be decreased when used in combination with Betaxolol.
DB01186
The therapeutic efficacy of Pergolide can be decreased when used in combination with Betaxolol.
DB01253
The therapeutic efficacy of Ergometrine can be decreased when used in combination with Betaxolol.
DB01274
The therapeutic efficacy of Arformoterol can be decreased when used in combination with Betaxolol.
DB01288
The therapeutic efficacy of Fenoterol can be decreased when used in combination with Betaxolol.
DB01291
The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Betaxolol.
DB01363
The therapeutic efficacy of Ephedra sinica root can be decreased when used in combination with Betaxolol.
DB01364
The therapeutic efficacy of Ephedrine can be decreased when used in combination with Betaxolol.
DB01366
The therapeutic efficacy of Procaterol can be decreased when used in combination with Betaxolol.
DB01407
The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Betaxolol.
DB01408
The therapeutic efficacy of Bambuterol can be decreased when used in combination with Betaxolol.
DB01472
The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Betaxolol.
DB01537
The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Betaxolol.
DB01579
The therapeutic efficacy of Phendimetrazine can be decreased when used in combination with Betaxolol.
DB04948
The therapeutic efficacy of Lofexidine can be decreased when used in combination with Betaxolol.
DB05039
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Betaxolol.
DB05395
The therapeutic efficacy of Amibegron can be decreased when used in combination with Betaxolol.
DB06190
The therapeutic efficacy of Solabegron can be decreased when used in combination with Betaxolol.
DB06262
The therapeutic efficacy of Droxidopa can be decreased when used in combination with Betaxolol.
DB06706
The therapeutic efficacy of Isometheptene can be decreased when used in combination with Betaxolol.
DB06707
The therapeutic efficacy of Levonordefrin can be decreased when used in combination with Betaxolol.
DB06711
The therapeutic efficacy of Naphazoline can be decreased when used in combination with Betaxolol.
DB06764
The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Betaxolol.
DB06814
The therapeutic efficacy of Protokylol can be decreased when used in combination with Betaxolol.
DB08925
The therapeutic efficacy of Adrafinil can be decreased when used in combination with Betaxolol.
DB08941
The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Betaxolol.
DB08957
The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Betaxolol.
DB08985
The therapeutic efficacy of Etilefrine can be decreased when used in combination with Betaxolol.
DB09080
The therapeutic efficacy of Olodaterol can be decreased when used in combination with Betaxolol.
DB09082
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Betaxolol.
DB09202
The therapeutic efficacy of Cirazoline can be decreased when used in combination with Betaxolol.
DB09203
The therapeutic efficacy of Synephrine can be decreased when used in combination with Betaxolol.
DB09242
The therapeutic efficacy of Moxonidine can be decreased when used in combination with Betaxolol.
DB09273
The therapeutic efficacy of Doxofylline can be decreased when used in combination with Betaxolol.
DB11124
The therapeutic efficacy of Racepinephrine can be decreased when used in combination with Betaxolol.
DB11278
The therapeutic efficacy of DL-Methylephedrine can be decreased when used in combination with Betaxolol.
DB11373
The therapeutic efficacy of Amitraz can be decreased when used in combination with Betaxolol.
DB11428
The therapeutic efficacy of Medetomidine can be decreased when used in combination with Betaxolol.
DB11477
The therapeutic efficacy of Xylazine can be decreased when used in combination with Betaxolol.
DB11541
The therapeutic efficacy of Ractopamine can be decreased when used in combination with Betaxolol.
DB11543
The therapeutic efficacy of Romifidine can be decreased when used in combination with Betaxolol.
DB11556
The therapeutic efficacy of Detomidine can be decreased when used in combination with Betaxolol.
DB11587
The therapeutic efficacy of Etafedrine can be decreased when used in combination with Betaxolol.
DB11738
The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Betaxolol.
DB11871
The therapeutic efficacy of PF-00610355 can be decreased when used in combination with Betaxolol.
DB12100
The therapeutic efficacy of Abediterol can be decreased when used in combination with Betaxolol.
DB12248
The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Betaxolol.
DB12313
The therapeutic efficacy of Dopexamine can be decreased when used in combination with Betaxolol.
DB12526
The therapeutic efficacy of Batefenterol can be decreased when used in combination with Betaxolol.
DB12779
The therapeutic efficacy of Higenamine can be decreased when used in combination with Betaxolol.
DB12846
The therapeutic efficacy of Reproterol can be decreased when used in combination with Betaxolol.
DB13139
The therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Betaxolol.
DB13251
The therapeutic efficacy of Octopamine can be decreased when used in combination with Betaxolol.
DB13378
The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Betaxolol.
DB13398
The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Betaxolol.
DB13559
The therapeutic efficacy of Rimiterol can be decreased when used in combination with Betaxolol.
DB13692
The therapeutic efficacy of Tretoquinol can be decreased when used in combination with Betaxolol.
DB13777
The therapeutic efficacy of Prenalterol can be decreased when used in combination with Betaxolol.
DB13781
The therapeutic efficacy of Xamoterol can be decreased when used in combination with Betaxolol.
DB14752
The therapeutic efficacy of Racephedrine can be decreased when used in combination with Betaxolol.
DB14547
The therapeutic efficacy of Chloride ion can be decreased when used in combination with Betaxolol.
DB00761
Betaxolol may increase the hyperkalemic activities of Potassium chloride.
DB09125
Betaxolol may increase the hyperkalemic activities of Potassium citrate.
DB11098
Betaxolol may increase the hyperkalemic activities of Potassium bicarbonate.
DB14498
Betaxolol may increase the hyperkalemic activities of Potassium acetate.
DB09087
Potassium alum may increase the hyperkalemic activities of Betaxolol.
DB09413
Monopotassium phosphate may increase the hyperkalemic activities of Betaxolol.
DB09414
Dipotassium phosphate may increase the hyperkalemic activities of Betaxolol.
DB09449
Sodium phosphate, monobasic may increase the hyperkalemic activities of Betaxolol.
DB09483
Potassium lactate may increase the hyperkalemic activities of Betaxolol.
DB11090
Potassium nitrate may increase the hyperkalemic activities of Betaxolol.
DB11107
Potassium bitartrate may increase the hyperkalemic activities of Betaxolol.
DB11153
Potassium hydroxide may increase the hyperkalemic activities of Betaxolol.
DB13620
Potassium gluconate may increase the hyperkalemic activities of Betaxolol.
DB13735
Potassium guaiacolsulfonate may increase the hyperkalemic activities of Betaxolol.
DB13831
Potassium permanganate may increase the hyperkalemic activities of Betaxolol.
DB13977
Potassium carbonate may increase the hyperkalemic activities of Betaxolol.
DB14492
Potassium triiodide may increase the hyperkalemic activities of Betaxolol.
DB14499
Potassium sulfate may increase the hyperkalemic activities of Betaxolol.
DB14500
Potassium may increase the hyperkalemic activities of Betaxolol.
DB06715
Potassium Iodide may increase the hyperkalemic activities of Betaxolol.
DB09418
Potassium perchlorate may increase the hyperkalemic activities of Betaxolol.
DB01345
Betaxolol may increase the hyperkalemic activities of Potassium cation.
DB09061
The metabolism of Betaxolol can be decreased when combined with Cannabidiol.
DB00333
The metabolism of Betaxolol can be decreased when combined with Methadone.
DB00439
The metabolism of Betaxolol can be decreased when combined with Cerivastatin.
DB00574
The metabolism of Betaxolol can be decreased when combined with Fenfluramine.
DB00647
The metabolism of Betaxolol can be decreased when combined with Dextropropoxyphene.
DB00792
The metabolism of Betaxolol can be decreased when combined with Tripelennamine.
DB00810
The metabolism of Betaxolol can be decreased when combined with Biperiden.
DB00997
The metabolism of Betaxolol can be decreased when combined with Doxorubicin.
DB01005
The metabolism of Betaxolol can be decreased when combined with Hydroxyurea.
DB01075
The metabolism of Betaxolol can be decreased when combined with Diphenhydramine.
DB01110
The metabolism of Betaxolol can be decreased when combined with Miconazole.
DB01128
The metabolism of Betaxolol can be decreased when combined with Bicalutamide.
DB01233
The metabolism of Betaxolol can be decreased when combined with Metoclopramide.
DB05271
The metabolism of Betaxolol can be decreased when combined with Rotigotine.
DB06204
The metabolism of Betaxolol can be decreased when combined with Tapentadol.
DB06370
The metabolism of Betaxolol can be decreased when combined with Indisulam.
DB06412
The metabolism of Betaxolol can be decreased when combined with Oxymetholone.
DB09049
The metabolism of Betaxolol can be decreased when combined with Naloxegol.
DB11633
The metabolism of Betaxolol can be decreased when combined with Isavuconazole.
DB11638
The metabolism of Betaxolol can be decreased when combined with Artenimol.
DB01062
The metabolism of Betaxolol can be decreased when combined with Oxybutynin.
DB01093
The metabolism of Betaxolol can be decreased when combined with Dimethyl sulfoxide.
DB00972
The metabolism of Betaxolol can be decreased when combined with Azelastine.
DB00220
The metabolism of Betaxolol can be decreased when combined with Nelfinavir.
DB06691
The metabolism of Betaxolol can be decreased when combined with Mepyramine.
DB01096
The metabolism of Betaxolol can be decreased when combined with Oxamniquine.
DB01562
The metabolism of Betaxolol can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
DB14009
The metabolism of Betaxolol can be decreased when combined with Medical Cannabis.
DB14011
The metabolism of Betaxolol can be decreased when combined with Nabiximols.
DB14635
The metabolism of Betaxolol can be decreased when combined with Curcumin sulfate.
DB01590
The metabolism of Betaxolol can be decreased when combined with Everolimus.
DB00627
The metabolism of Betaxolol can be decreased when combined with Niacin.
DB12500
The metabolism of Betaxolol can be decreased when combined with Fedratinib.
DB00209
The metabolism of Betaxolol can be decreased when combined with Trospium.
DB00227
The metabolism of Betaxolol can be decreased when combined with Lovastatin.
DB00234
The metabolism of Betaxolol can be decreased when combined with Reboxetine.
DB00238
The metabolism of Betaxolol can be decreased when combined with Nevirapine.
DB00317
The metabolism of Betaxolol can be decreased when combined with Gefitinib.
DB00361
The metabolism of Betaxolol can be decreased when combined with Vinorelbine.
DB00448
The metabolism of Betaxolol can be decreased when combined with Lansoprazole.
DB00494
The metabolism of Betaxolol can be decreased when combined with Entacapone.
DB00570
The metabolism of Betaxolol can be decreased when combined with Vinblastine.
DB00921
The metabolism of Betaxolol can be decreased when combined with Buprenorphine.
DB01131
The metabolism of Betaxolol can be decreased when combined with Proguanil.
DB01323
The metabolism of Betaxolol can be decreased when combined with St. John's Wort.
DB04938
The metabolism of Betaxolol can be decreased when combined with Ospemifene.
DB06287
The metabolism of Betaxolol can be decreased when combined with Temsirolimus.
DB06512
The metabolism of Betaxolol can be decreased when combined with Deramciclane.
DB09065
The metabolism of Betaxolol can be decreased when combined with Cobicistat.
DB04911
The metabolism of Betaxolol can be decreased when combined with Oritavancin.
DB00193
The metabolism of Betaxolol can be decreased when combined with Tramadol.
DB00216
The metabolism of Eletriptan can be decreased when combined with Betaxolol.
DB00318
The metabolism of Codeine can be decreased when combined with Betaxolol.
DB00377
The metabolism of Palonosetron can be decreased when combined with Betaxolol.
DB00396
The metabolism of Progesterone can be decreased when combined with Betaxolol.
DB00409
The metabolism of Remoxipride can be decreased when combined with Betaxolol.
DB00490
The metabolism of Buspirone can be decreased when combined with Betaxolol.
DB00497
The metabolism of Oxycodone can be decreased when combined with Betaxolol.
DB00514
The metabolism of Dextromethorphan can be decreased when combined with Betaxolol.
DB00592
The metabolism of Piperazine can be decreased when combined with Betaxolol.
DB00641
The metabolism of Simvastatin can be decreased when combined with Betaxolol.
DB00701
The metabolism of Amprenavir can be decreased when combined with Betaxolol.
DB00737
The metabolism of Meclizine can be decreased when combined with Betaxolol.
DB00918
The metabolism of Almotriptan can be decreased when combined with Betaxolol.
DB01028
The metabolism of Methoxyflurane can be decreased when combined with Betaxolol.
DB01095
The metabolism of Fluvastatin can be decreased when combined with Betaxolol.
DB01177
The metabolism of Idarubicin can be decreased when combined with Betaxolol.
DB01192
The metabolism of Oxymorphone can be decreased when combined with Betaxolol.
DB01409
The metabolism of Tiotropium can be decreased when combined with Betaxolol.
DB01466
The metabolism of Ethylmorphine can be decreased when combined with Betaxolol.
DB01551
The metabolism of Dihydrocodeine can be decreased when combined with Betaxolol.
DB04905
The metabolism of Tesmilifene can be decreased when combined with Betaxolol.
DB06016
The metabolism of Cariprazine can be decreased when combined with Betaxolol.
DB06144
The metabolism of Sertindole can be decreased when combined with Betaxolol.
DB06506
The metabolism of Repinotan can be decreased when combined with Betaxolol.
DB06608
The metabolism of Tafenoquine can be decreased when combined with Betaxolol.
DB06678
The metabolism of Esmirtazapine can be decreased when combined with Betaxolol.
DB06702
The metabolism of Fesoterodine can be decreased when combined with Betaxolol.
DB06735
The metabolism of Enclomiphene can be decreased when combined with Betaxolol.
DB08922
The metabolism of Perospirone can be decreased when combined with Betaxolol.
DB09048
The metabolism of Netupitant can be decreased when combined with Betaxolol.
DB09053
The metabolism of Ibrutinib can be decreased when combined with Betaxolol.
DB09068
The metabolism of Vortioxetine can be decreased when combined with Betaxolol.
DB09076
The metabolism of Umeclidinium can be decreased when combined with Betaxolol.
DB09183
The metabolism of Dasabuvir can be decreased when combined with Betaxolol.
DB09195
The metabolism of Lorpiprazole can be decreased when combined with Betaxolol.
DB11130
The metabolism of Opium can be decreased when combined with Betaxolol.
DB11855
The metabolism of Revefenacin can be decreased when combined with Betaxolol.
DB11915
The metabolism of Valbenazine can be decreased when combined with Betaxolol.
DB11979
The metabolism of Elagolix can be decreased when combined with Betaxolol.
DB12070
The metabolism of Letermovir can be decreased when combined with Betaxolol.
DB13293
The metabolism of Ipecac can be decreased when combined with Betaxolol.
DB09173
The metabolism of Butyrfentanyl can be decreased when combined with Betaxolol.
DB01410
The metabolism of Ciclesonide can be decreased when combined with Betaxolol.
DB00252
The metabolism of Phenytoin can be decreased when combined with Betaxolol.
DB14881
The metabolism of Oliceridine can be decreased when combined with Betaxolol.
DB00530
The metabolism of Erlotinib can be decreased when combined with Betaxolol.
DB00637
The metabolism of Astemizole can be decreased when combined with Betaxolol.
DB00675
The metabolism of Betaxolol can be decreased when combined with Tamoxifen.
DB11963
The metabolism of Betaxolol can be decreased when combined with Dacomitinib.
DB05109
The metabolism of Trabectedin can be decreased when combined with Betaxolol.
DB08901
The metabolism of Ponatinib can be decreased when combined with Betaxolol.
DB00277
The metabolism of Theophylline can be decreased when combined with Betaxolol.
DB01100
The metabolism of Pimozide can be decreased when combined with Betaxolol.
DB13874
The metabolism of Betaxolol can be decreased when combined with Enasidenib.
DB00321
The metabolism of Amitriptyline can be decreased when combined with Betaxolol.
DB00543
The metabolism of Betaxolol can be decreased when combined with Amoxapine.
DB00726
The metabolism of Betaxolol can be decreased when combined with Trimipramine.
DB01242
The metabolism of Betaxolol can be decreased when combined with Clomipramine.
DB00540
The metabolism of Betaxolol can be decreased when combined with Nortriptyline.
DB09185
The metabolism of Betaxolol can be decreased when combined with Viloxazine.
DB05015
The metabolism of Betaxolol can be increased when combined with Belinostat.
DB00170
The metabolism of Betaxolol can be increased when combined with Menadione.
DB00428
The metabolism of Betaxolol can be increased when combined with Streptozocin.
DB00607
The metabolism of Betaxolol can be increased when combined with Nafcillin.
DB00745
The metabolism of Betaxolol can be increased when combined with Modafinil.
DB01129
The metabolism of Betaxolol can be increased when combined with Rabeprazole.
DB05928
The metabolism of Betaxolol can be increased when combined with Dovitinib.
DB06413
The metabolism of Betaxolol can be increased when combined with Armodafinil.
DB06732
The metabolism of Betaxolol can be increased when combined with beta-Naphthoflavone.
DB00400
The metabolism of Betaxolol can be increased when combined with Griseofulvin.
DB01320
The metabolism of Betaxolol can be increased when combined with Fosphenytoin.
DB00338
The metabolism of Betaxolol can be increased when combined with Omeprazole.
DB00454
The metabolism of Betaxolol can be increased when combined with Meperidine.
DB00008
The metabolism of Betaxolol can be decreased when combined with Peginterferon alfa-2a.
DB00011
The metabolism of Betaxolol can be decreased when combined with Interferon alfa-n1.
DB00018
The metabolism of Betaxolol can be decreased when combined with Interferon alfa-n3.
DB00033
The metabolism of Betaxolol can be decreased when combined with Interferon gamma-1b.
DB00034
The metabolism of Betaxolol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00060
The metabolism of Betaxolol can be decreased when combined with Interferon beta-1a.
DB00068
The metabolism of Betaxolol can be decreased when combined with Interferon beta-1b.
DB00069
The metabolism of Betaxolol can be decreased when combined with Interferon alfacon-1.
DB00105
The metabolism of Betaxolol can be decreased when combined with Interferon alfa-2b.
DB00208
The metabolism of Betaxolol can be decreased when combined with Ticlopidine.
DB00435
The metabolism of Betaxolol can be decreased when combined with Nitric Oxide.
DB00553
The metabolism of Betaxolol can be decreased when combined with Methoxsalen.
DB00730
The metabolism of Betaxolol can be decreased when combined with Thiabendazole.
DB00951
The metabolism of Betaxolol can be decreased when combined with Isoniazid.
DB01241
The metabolism of Betaxolol can be decreased when combined with Gemfibrozil.
DB02709
The metabolism of Betaxolol can be decreased when combined with Resveratrol.
DB04574
The metabolism of Betaxolol can be decreased when combined with Estrone sulfate.
DB05396
The metabolism of Betaxolol can be decreased when combined with Albinterferon Alfa-2B.
DB05990
The metabolism of Betaxolol can be decreased when combined with Obeticholic acid.
DB06803
The metabolism of Betaxolol can be decreased when combined with Niclosamide.
DB09118
The metabolism of Betaxolol can be decreased when combined with Stiripentol.
DB09122
The metabolism of Betaxolol can be decreased when combined with Peginterferon beta-1a.
DB11198
The metabolism of Betaxolol can be decreased when combined with Peppermint oil.
DB11404
The metabolism of Betaxolol can be decreased when combined with Enrofloxacin.
DB11994
The metabolism of Betaxolol can be decreased when combined with Diacerein.
DB12945
The metabolism of Betaxolol can be decreased when combined with Dihydralazine.
DB13952
The metabolism of Betaxolol can be decreased when combined with Estradiol acetate.
DB13953
The metabolism of Betaxolol can be decreased when combined with Estradiol benzoate.
DB13954
The metabolism of Betaxolol can be decreased when combined with Estradiol cypionate.
DB13955
The metabolism of Betaxolol can be decreased when combined with Estradiol dienanthate.
DB13956
The metabolism of Betaxolol can be decreased when combined with Estradiol valerate.
DB13975
The metabolism of Betaxolol can be decreased when combined with Black cohosh.
DB15119
The metabolism of Betaxolol can be decreased when combined with Ropeginterferon alfa-2b.
DB15131
The metabolism of Betaxolol can be decreased when combined with Interferon alfa-2c.
DB06442
The metabolism of Betaxolol can be decreased when combined with Avasimibe.
DB12814
The metabolism of Betaxolol can be decreased when combined with Cepeginterferon alfa-2B.
DB11791
The metabolism of Betaxolol can be decreased when combined with Capmatinib.
DB05258
The metabolism of Betaxolol can be decreased when combined with Interferon alfa.
DB05708
The metabolism of GTS-21 can be decreased when combined with Betaxolol.
DB00184
The metabolism of Betaxolol can be decreased when combined with Nicotine.
DB00262
The metabolism of Carmustine can be decreased when combined with Betaxolol.
DB00286
The metabolism of Conjugated estrogens can be decreased when combined with Betaxolol.
DB00296
The metabolism of Ropivacaine can be decreased when combined with Betaxolol.
DB00315
The metabolism of Zolmitriptan can be decreased when combined with Betaxolol.
DB00316
The metabolism of Acetaminophen can be decreased when combined with Betaxolol.
DB00356
The metabolism of Chlorzoxazone can be decreased when combined with Betaxolol.
DB00382
The metabolism of Tacrine can be decreased when combined with Betaxolol.
DB00384
The metabolism of Triamterene can be decreased when combined with Betaxolol.
DB00425
The metabolism of Zolpidem can be decreased when combined with Betaxolol.
DB00442
The metabolism of Entecavir can be decreased when combined with Betaxolol.
DB00499
The metabolism of Flutamide can be decreased when combined with Betaxolol.
DB00518
The metabolism of Albendazole can be decreased when combined with Betaxolol.
DB00642
The metabolism of Pemetrexed can be decreased when combined with Betaxolol.
DB00682
The metabolism of Warfarin can be decreased when combined with Betaxolol.
DB00740
The metabolism of Riluzole can be decreased when combined with Betaxolol.
DB00744
The metabolism of Zileuton can be decreased when combined with Betaxolol.
DB00758
The metabolism of Clopidogrel can be decreased when combined with Betaxolol.
DB00773
The metabolism of Etoposide can be decreased when combined with Betaxolol.
DB00787
The metabolism of Acyclovir can be decreased when combined with Betaxolol.
DB00851
The metabolism of Dacarbazine can be decreased when combined with Betaxolol.
DB00863
The metabolism of Ranitidine can be decreased when combined with Betaxolol.
DB00980
The metabolism of Ramelteon can be decreased when combined with Betaxolol.
DB00993
The metabolism of Azathioprine can be decreased when combined with Betaxolol.
DB00998
The metabolism of Frovatriptan can be decreased when combined with Betaxolol.
DB01002
The metabolism of Levobupivacaine can be decreased when combined with Betaxolol.
DB01058
The metabolism of Praziquantel can be decreased when combined with Betaxolol.
DB01065
The metabolism of Melatonin can be decreased when combined with Betaxolol.
DB01094
The metabolism of Hesperetin can be decreased when combined with Betaxolol.
DB01191
The metabolism of Dexfenfluramine can be decreased when combined with Betaxolol.
DB01418
The metabolism of Acenocoumarol can be decreased when combined with Betaxolol.
DB01558
The metabolism of Bromazepam can be decreased when combined with Betaxolol.
DB01623
The metabolism of Thiothixene can be decreased when combined with Betaxolol.
DB01645
The metabolism of Genistein can be decreased when combined with Betaxolol.
DB03783
The metabolism of Phenacetin can be decreased when combined with Betaxolol.
DB06148
The metabolism of Mianserin can be decreased when combined with Betaxolol.
DB06210
The metabolism of Eltrombopag can be decreased when combined with Betaxolol.
DB06235
The metabolism of Vadimezan can be decreased when combined with Betaxolol.
DB06594
The metabolism of Agomelatine can be decreased when combined with Betaxolol.
DB06626
The metabolism of Axitinib can be decreased when combined with Betaxolol.
DB06769
The metabolism of Bendamustine can be decreased when combined with Betaxolol.
DB06770
The metabolism of Benzyl alcohol can be decreased when combined with Betaxolol.
DB06774
The metabolism of Capsaicin can be decreased when combined with Betaxolol.
DB08496
The metabolism of (R)-warfarin can be decreased when combined with Betaxolol.
DB08883
The metabolism of Perampanel can be decreased when combined with Betaxolol.
DB08910
The metabolism of Pomalidomide can be decreased when combined with Betaxolol.
DB09071
The metabolism of Tasimelteon can be decreased when combined with Betaxolol.
DB09225
The metabolism of Zotepine can be decreased when combined with Betaxolol.
DB09256
The metabolism of Tegafur can be decreased when combined with Betaxolol.
DB09290
The metabolism of Ramosetron can be decreased when combined with Betaxolol.
DB11967
The metabolism of Binimetinib can be decreased when combined with Betaxolol.
DB12026
The metabolism of Voxilaprevir can be decreased when combined with Betaxolol.
DB11757
The metabolism of Istradefylline can be decreased when combined with Betaxolol.
DB00924
The metabolism of Cyclobenzaprine can be decreased when combined with Betaxolol.
DB04889
The metabolism of Bicifadine can be decreased when combined with Betaxolol.
DB00783
The metabolism of Estradiol can be decreased when combined with Betaxolol.
DB00977
The metabolism of Ethinylestradiol can be decreased when combined with Betaxolol.
DB01142
The metabolism of Doxepin can be decreased when combined with Betaxolol.
DB00532
The metabolism of Mephenytoin can be decreased when combined with Betaxolol.
DB11689
The metabolism of Selumetinib can be decreased when combined with Betaxolol.
DB00188
The metabolism of Betaxolol can be decreased when combined with Bortezomib.
DB00655
The metabolism of Estrone can be decreased when combined with Betaxolol.
DB04951
The metabolism of Pirfenidone can be decreased when combined with Betaxolol.
DB00299
The metabolism of Penciclovir can be decreased when combined with Betaxolol.
DB00467
The metabolism of Betaxolol can be decreased when combined with Enoxacin.
DB00537
The metabolism of Betaxolol can be decreased when combined with Ciprofloxacin.
DB00549
The metabolism of Betaxolol can be decreased when combined with Zafirlukast.
DB05488
The metabolism of Betaxolol can be decreased when combined with Technetium Tc-99m ciprofloxacin.
DB06595
The metabolism of Betaxolol can be decreased when combined with Midostaurin.
DB14025
The metabolism of Betaxolol can be decreased when combined with Clinafloxacin.
DB14029
The metabolism of Betaxolol can be decreased when combined with Furafylline.
DB00181
The risk or severity of adverse effects can be increased when Baclofen is combined with Betaxolol.
DB00258
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium acetate.
DB00326
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium glucoheptonate.
DB01164
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium chloride.
DB01373
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium.
DB06724
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium carbonate.
DB11093
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium citrate.
DB11126
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium gluconate.
DB11348
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium Phosphate.
DB13142
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium glubionate anhydrous.
DB13231
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium lactate.
DB13365
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium lactate gluconate.
DB13590
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium pangamate.
DB13800
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium levulinate.
DB14577
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium cation.
DB14684
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium polycarbophil.
DB13917
The therapeutic efficacy of Betaxolol can be increased when used in combination with Deoxyepinephrine.
DB00005
The metabolism of Betaxolol can be increased when combined with Etanercept.
DB00026
The metabolism of Betaxolol can be increased when combined with Anakinra.
DB00051
The metabolism of Betaxolol can be increased when combined with Adalimumab.
DB00065
The metabolism of Betaxolol can be increased when combined with Infliximab.
DB01281
The metabolism of Betaxolol can be increased when combined with Abatacept.
DB04956
The metabolism of Betaxolol can be increased when combined with Afelimomab.
DB05676
The metabolism of Betaxolol can be increased when combined with Apremilast.
DB06168
The metabolism of Betaxolol can be increased when combined with Canakinumab.
DB06273
The metabolism of Betaxolol can be increased when combined with Tocilizumab.
DB06372
The metabolism of Betaxolol can be increased when combined with Rilonacept.
DB06674
The metabolism of Betaxolol can be increased when combined with Golimumab.
DB08904
The metabolism of Betaxolol can be increased when combined with Certolizumab pegol.
DB09029
The metabolism of Betaxolol can be increased when combined with Secukinumab.
DB09036
The metabolism of Betaxolol can be increased when combined with Siltuximab.
DB14724
The metabolism of Betaxolol can be increased when combined with Emapalumab.
DB00182
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Amphetamine.
DB00191
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Phentermine.
DB00852
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Pseudoephedrine.
DB00865
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Benzphetamine.
DB00937
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Diethylpropion.
DB01255
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Lisdexamfetamine.
DB01365
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Mephentermine.
DB01442
The therapeutic efficacy of Betaxolol can be decreased when used in combination with MMDA.
DB01454
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Midomafetamine.
DB01467
The therapeutic efficacy of Betaxolol can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.
DB01484
The therapeutic efficacy of Betaxolol can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.
DB01509
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Tenamfetamine.
DB01556
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Chlorphentermine.
DB01566
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Methylenedioxyethamphetamine.
DB01576
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Dextroamphetamine.
DB01577
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Metamfetamine.
DB09480
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Iofetamine I-123.
DB12080
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Ritobegron.
DB13108
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Mephedrone.
DB13624
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Methoxyphenamine.
DB13703
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Gepefrine.
DB13940
The therapeutic efficacy of Betaxolol can be decreased when used in combination with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB00190
The risk or severity of hypotension can be increased when Carbidopa is combined with Betaxolol.
DB00228
Enflurane may increase the cardiodepressant activities of Betaxolol.
DB00024
The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Betaxolol.
DB00279
The therapeutic efficacy of Liothyronine can be decreased when used in combination with Betaxolol.
DB00451
The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Betaxolol.
DB01583
The therapeutic efficacy of Liotrix can be decreased when used in combination with Betaxolol.
DB03604
The therapeutic efficacy of Tiratricol can be decreased when used in combination with Betaxolol.
DB09100
The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Betaxolol.
DB00457
The risk or severity of hypotension can be increased when Prazosin is combined with Betaxolol.
DB01238
The risk or severity of hypotension can be increased when Aripiprazole is combined with Betaxolol.
DB14185
The risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Betaxolol.
DB00373
The risk or severity of adverse effects can be increased when Timolol is combined with Betaxolol.
DB00612
The risk or severity of adverse effects can be increased when Bisoprolol is combined with Betaxolol.
DB00575
The risk or severity of hypotension can be increased when Clonidine is combined with Betaxolol.
DB00656
The risk or severity of QTc prolongation can be increased when Trazodone is combined with Betaxolol.
DB00040
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Glucagon.
DB00414
The therapeutic efficacy of Acetohexamide can be increased when used in combination with Betaxolol.
DB00672
The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Betaxolol.
DB00839
The therapeutic efficacy of Tolazamide can be increased when used in combination with Betaxolol.
DB01016
The therapeutic efficacy of Glyburide can be increased when used in combination with Betaxolol.
DB01067
The therapeutic efficacy of Glipizide can be increased when used in combination with Betaxolol.
DB01120
The therapeutic efficacy of Gliclazide can be increased when used in combination with Betaxolol.
DB01124
The therapeutic efficacy of Tolbutamide can be increased when used in combination with Betaxolol.
DB01251
The therapeutic efficacy of Gliquidone can be increased when used in combination with Betaxolol.
DB01289
The therapeutic efficacy of Glisoxepide can be increased when used in combination with Betaxolol.
DB08962
The therapeutic efficacy of Glibornuride can be increased when used in combination with Betaxolol.
DB13406
The therapeutic efficacy of Carbutamide can be increased when used in combination with Betaxolol.
DB13675
The therapeutic efficacy of Metahexamide can be increased when used in combination with Betaxolol.
DB00834
The therapeutic efficacy of Mifepristone can be increased when used in combination with Betaxolol.
DB00263
The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Betaxolol.
DB00738
The therapeutic efficacy of Pentamidine can be increased when used in combination with Betaxolol.
DB01015
The therapeutic efficacy of Betaxolol can be increased when used in combination with Sulfamethoxazole.
DB01268
The therapeutic efficacy of Betaxolol can be increased when used in combination with Sunitinib.
DB08907
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Betaxolol.
DB01200
The therapeutic efficacy of Bromocriptine can be increased when used in combination with Betaxolol.
DB09038
The therapeutic efficacy of Betaxolol can be increased when used in combination with Empagliflozin.
DB09198
The therapeutic efficacy of Betaxolol can be increased when used in combination with Lobeglitazone.
DB00731
The therapeutic efficacy of Nateglinide can be increased when used in combination with Betaxolol.
DB00914
The therapeutic efficacy of Phenformin can be increased when used in combination with Betaxolol.
DB06203
The therapeutic efficacy of Alogliptin can be increased when used in combination with Betaxolol.
DB00030
The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin human.
DB00046
The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin lispro.
DB00047
The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin glargine.
DB00071
The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin pork.
DB01306
The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin aspart.
DB01307
The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin detemir.
DB01309
The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin glulisine.
DB05115
The therapeutic efficacy of Betaxolol can be increased when used in combination with NN344.
DB09564
The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin degludec.
DB11567
The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin peglispro.
DB11568
The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin tregopil.
DB00412
The therapeutic efficacy of Betaxolol can be increased when used in combination with Rosiglitazone.
DB06292
The therapeutic efficacy of Betaxolol can be increased when used in combination with Dapagliflozin.
DB09456
The therapeutic efficacy of Insulin beef can be increased when used in combination with Betaxolol.
DB00197
The therapeutic efficacy of Troglitazone can be increased when used in combination with Betaxolol.
DB00284
The therapeutic efficacy of Acarbose can be increased when used in combination with Betaxolol.
DB00331
The therapeutic efficacy of Metformin can be increased when used in combination with Betaxolol.
DB00359
The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Betaxolol.
DB00491
The therapeutic efficacy of Miglitol can be increased when used in combination with Betaxolol.
DB00912
The therapeutic efficacy of Repaglinide can be increased when used in combination with Betaxolol.
DB01132
The therapeutic efficacy of Pioglitazone can be increased when used in combination with Betaxolol.
DB01252
The therapeutic efficacy of Mitiglinide can be increased when used in combination with Betaxolol.
DB01261
The therapeutic efficacy of Sitagliptin can be increased when used in combination with Betaxolol.
DB01276
The therapeutic efficacy of Exenatide can be increased when used in combination with Betaxolol.
DB01277
The therapeutic efficacy of Mecasermin can be increased when used in combination with Betaxolol.
DB01278
The therapeutic efficacy of Pramlintide can be increased when used in combination with Betaxolol.
DB01382
The therapeutic efficacy of Glymidine can be increased when used in combination with Betaxolol.
DB01700
The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Betaxolol.
DB04830
The therapeutic efficacy of Buformin can be increased when used in combination with Betaxolol.
DB04876
The therapeutic efficacy of Vildagliptin can be increased when used in combination with Betaxolol.
DB04878
The therapeutic efficacy of Voglibose can be increased when used in combination with Betaxolol.
DB05819
The therapeutic efficacy of NBI-6024 can be increased when used in combination with Betaxolol.
DB06011
The therapeutic efficacy of AMG-222 can be increased when used in combination with Betaxolol.
DB06127
The therapeutic efficacy of Bisegliptin can be increased when used in combination with Betaxolol.
DB06335
The therapeutic efficacy of Saxagliptin can be increased when used in combination with Betaxolol.
DB06655
The therapeutic efficacy of Liraglutide can be increased when used in combination with Betaxolol.
DB08382
The therapeutic efficacy of Gosogliptin can be increased when used in combination with Betaxolol.
DB08882
The therapeutic efficacy of Linagliptin can be increased when used in combination with Betaxolol.
DB09022
The therapeutic efficacy of Benfluorex can be increased when used in combination with Betaxolol.
DB09043
The therapeutic efficacy of Albiglutide can be increased when used in combination with Betaxolol.
DB09045
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Betaxolol.
DB09199
The therapeutic efficacy of Netoglitazone can be increased when used in combination with Betaxolol.
DB09200
The therapeutic efficacy of Rivoglitazone can be increased when used in combination with Betaxolol.
DB09201
The therapeutic efficacy of Ciglitazone can be increased when used in combination with Betaxolol.
DB09265
The therapeutic efficacy of Lixisenatide can be increased when used in combination with Betaxolol.
DB11698
The therapeutic efficacy of Ipragliflozin can be increased when used in combination with Betaxolol.
DB11723
The therapeutic efficacy of Dutogliptin can be increased when used in combination with Betaxolol.
DB11780
The therapeutic efficacy of Allicin can be increased when used in combination with Betaxolol.
DB11824
The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Betaxolol.
DB11827
The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Betaxolol.
DB11898
The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Betaxolol.
DB11950
The therapeutic efficacy of Teneligliptin can be increased when used in combination with Betaxolol.
DB11992
The therapeutic efficacy of Omarigliptin can be increased when used in combination with Betaxolol.
DB12268
The therapeutic efficacy of Carmegliptin can be increased when used in combination with Betaxolol.
DB12412
The therapeutic efficacy of Gemigliptin can be increased when used in combination with Betaxolol.
DB12417
The therapeutic efficacy of Anagliptin can be increased when used in combination with Betaxolol.
DB12625
The therapeutic efficacy of Evogliptin can be increased when used in combination with Betaxolol.
DB12713
The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Betaxolol.
DB12781
The therapeutic efficacy of Balaglitazone can be increased when used in combination with Betaxolol.
DB12935
The therapeutic efficacy of Remogliflozin etabonate can be increased when used in combination with Betaxolol.
DB13446
The therapeutic efficacy of Guar gum can be increased when used in combination with Betaxolol.
DB13928
The therapeutic efficacy of Semaglutide can be increased when used in combination with Betaxolol.
DB14027
The therapeutic efficacy of Taspoglutide can be increased when used in combination with Betaxolol.
DB14035
The therapeutic efficacy of Englitazone can be increased when used in combination with Betaxolol.
DB15171
The therapeutic efficacy of Tirzepatide can be increased when used in combination with Betaxolol.
DB15217
The therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Betaxolol.
DB11986
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Entrectinib.
DB11642
Pitolisant may increase the QTc-prolonging activities of Betaxolol.
DB12825
Lefamulin may increase the QTc-prolonging activities of Betaxolol.
DB00763
The excretion of Betaxolol can be decreased when combined with Methimazole.
DB01175
The serum concentration of Escitalopram can be increased when it is combined with Betaxolol.
DB01224
Betaxolol may increase the hypotensive activities of Quetiapine.
DB11732
Lasmiditan may increase the bradycardic activities of Betaxolol.
DB15066
The serum concentration of Betaxolol can be increased when it is combined with Givosiran.
DB00661
The risk or severity of adverse effects can be increased when Betaxolol is combined with Verapamil.
DB00243
The serum concentration of Betaxolol can be increased when it is combined with Ranolazine.
DB00557
The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Betaxolol.
DB00246
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Ziprasidone.
DB00999
The therapeutic efficacy of Betaxolol can be increased when used in combination with Hydrochlorothiazide.
DB00436
The therapeutic efficacy of Bendroflumethiazide can be increased when used in combination with Betaxolol.
DB00606
The therapeutic efficacy of Cyclothiazide can be increased when used in combination with Betaxolol.
DB00774
The therapeutic efficacy of Hydroflumethiazide can be increased when used in combination with Betaxolol.
DB00880
The therapeutic efficacy of Chlorothiazide can be increased when used in combination with Betaxolol.
DB01021
The therapeutic efficacy of Trichlormethiazide can be increased when used in combination with Betaxolol.
DB01324
The therapeutic efficacy of Polythiazide can be increased when used in combination with Betaxolol.
DB13532
The therapeutic efficacy of Cyclopenthiazide can be increased when used in combination with Betaxolol.
DB00232
The therapeutic efficacy of Betaxolol can be increased when used in combination with Methyclothiazide.
DB00562
The therapeutic efficacy of Betaxolol can be increased when used in combination with Benzthiazide.
DB13430
The therapeutic efficacy of Betaxolol can be increased when used in combination with Mebutizide.
DB00502
The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Haloperidol.
DB00472
The serum concentration of Betaxolol can be increased when it is combined with Fluoxetine.
DB00808
The therapeutic efficacy of Betaxolol can be increased when used in combination with Indapamide.
DB00104
The serum concentration of the active metabolites of Betaxolol can be increased when Betaxolol is used in combination with Octreotide.
DB11932
The serum concentration of Betaxolol can be increased when it is combined with Abametapir.
DB15762
The serum concentration of Betaxolol can be decreased when it is combined with Satralizumab.

序列

实验性质

Water Solubility
451 mg/L

Melting Point
70-72 °C
PhysProp
logP
2.81
RECANATINI,M (1992)
caco2 Permeability
-4.81
ADME Research, USCD
pKa
9.4

外部标识符

resource：Drugs Product Database (DPD)
identifier：11219
resource：ChEBI
identifier：3082
resource：PubChem Compound
identifier：2369
resource：PubChem Substance
identifier：46506041
resource：KEGG Compound
identifier：C06849
resource：ChemSpider
identifier：2279
resource：BindingDB
identifier：50405521
resource：PharmGKB
identifier：PA448611
resource：Therapeutic Targets Database
identifier：DAP000305
resource：IUPHAR
identifier：549
resource：Guide to Pharmacology
identifier：549
resource：Wikipedia
identifier：Betaxolol
resource：ChEMBL
identifier：CHEMBL423
resource：RxCUI
identifier：1520

外部链接

RxList
http://www.rxlist.com/cgi/generic3/betaxolol.htm
Drugs.com
http://www.drugs.com/cdi/betaxolol-drops.html

路径

smpdb-id:SMP0000299
name:Betaxolol Action Pathway
category:drug_action
drugbank-id:DB00171
name:ATP
drugbank-id:DB00195
name:Betaxolol
drugbank-id:DB01345
name:Potassium cation
drugbank-id:DB01373
name:Calcium
drugbank-id:DB01378
name:Magnesium cation
enzymes_uniprot-id:P08588
enzymes_uniprot-id:P05023
enzymes_uniprot-id:P50993
enzymes_uniprot-id:P13637
enzymes_uniprot-id:Q13733
enzymes_uniprot-id:P05026
enzymes_uniprot-id:P14415
enzymes_uniprot-id:P54709
enzymes_uniprot-id:B7ZKV8
enzymes_uniprot-id:P54710
enzymes_uniprot-id:P63252
enzymes_uniprot-id:P48050
enzymes_uniprot-id:P48549
enzymes_uniprot-id:P48544
enzymes_uniprot-id:Q9UK17
enzymes_uniprot-id:Q9NS61
enzymes_uniprot-id:P22460
enzymes_uniprot-id:Q12959
enzymes_uniprot-id:P51787
enzymes_uniprot-id:P15382
enzymes_uniprot-id:Q9Y6J6
enzymes_uniprot-id:Q12809
enzymes_uniprot-id:Q5I7T1
enzymes_uniprot-id:Q09428
enzymes_uniprot-id:Q15842
enzymes_uniprot-id:Q14654
enzymes_uniprot-id:O60706
enzymes_uniprot-id:O00180
enzymes_uniprot-id:P32418
enzymes_uniprot-id:Q9Y3Q4
enzymes_uniprot-id:Q14524
enzymes_uniprot-id:Q13425
enzymes_uniprot-id:Q13884
enzymes_uniprot-id:Q13424
enzymes_uniprot-id:Q13936
enzymes_uniprot-id:Q9NY47
enzymes_uniprot-id:Q02641
enzymes_uniprot-id:P08172
enzymes_uniprot-id:Q92736
enzymes_uniprot-id:P16615
enzymes_uniprot-id:P26678
enzymes_uniprot-id:P17612
enzymes_uniprot-id:P10644
enzymes_uniprot-id:P62158
enzymes_uniprot-id:Q15746
enzymes_uniprot-id:P30556
enzymes_uniprot-id:Q9NQ66
enzymes_uniprot-id:P02585
enzymes_uniprot-id:P19237
enzymes_uniprot-id:P13805
enzymes_uniprot-id:P63316
enzymes_uniprot-id:P19429
enzymes_uniprot-id:P45379
enzymes_uniprot-id:P48788
enzymes_uniprot-id:P45378
enzymes_uniprot-id:P09493
enzymes_uniprot-id:P07951
enzymes_uniprot-id:O95180
enzymes_uniprot-id:O43497
enzymes_uniprot-id:Q14643

目标

id:BE0000172
name:Beta-1 adrenergic receptor
organism:Humans
action:antagonist
McLean AJ, Zeng FY, Behan D, Chalmers D, Milligan G: Generation and analysis of constitutively active and physically destabilized mutants of the human beta(1)-adrenoceptor. Mol Pharmacol. 2002 Sep;62(3):747-55.
Rudoy CA, Van Bockstaele EJ: Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1119-29. Epub 2007 Apr 19.
Satoh N, Suzuki J, Bessho H, Kitada Y, Narimatsu A, Tobe A: Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs: comparison with atenolol and propranolol. Jpn J Pharmacol. 1990 Oct;54(2):113-9.
Lesar TS: Comparison of ophthalmic beta-blocking agents. Clin Pharm. 1987 Jun;6(6):451-63.
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
known-action:yes
name:Beta-1 adrenergic receptor
general-function:Receptor signaling protein activity
specific-function:Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
gene-name:ADRB1
locus:10q24-q26
cellular-location:Cell membrane
transmembrane-regions:56-84 94-120 133-154 173-196 223-248 320-349 355-377
signal-regions:
theoretical-pi:9.03
molecular-weight:51322.1
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:285GenAtlasADRB1GenBank Gene DatabaseJ03019GenBank Protein Database178200IUPHAR28Guide to Pharmacology28UniProtKBP08588UniProt AccessionADRB1_HUMAN
synonyms:ADRB1RB1ARBeta-1 adrenoceptorBeta-1 adrenoreceptor
amino-acid-sequence:>lcl|BSEQ0010188|Beta-1 adrenergic receptor MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAG MGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVV WGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVC TVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM AFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAP LANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFV FFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRRHATHGDRPRASGCLARPGP PPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV
gene-sequence:>lcl|BSEQ0010189|Beta-1 adrenergic receptor (ADRB1) ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAG AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC TCGAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGTAG
pfams:PF000017tm_1
go-classifiers:componentearly endosomecomponentintegral component of plasma membranecomponentplasma membranefunctionalpha-2A adrenergic receptor bindingfunctionbeta-adrenergic receptor activityfunctionbeta1-adrenergic receptor activityfunctionepinephrine bindingfunctionnorepinephrine bindingfunctionPDZ domain bindingfunctionprotein heterodimerization activityfunctionRas guanyl-nucleotide exchange factor activityfunctionreceptor signaling protein activityprocessactivation of adenylate cyclase activityprocessadenylate cyclase-activating adrenergic receptor signaling pathwayprocessbrown fat cell differentiationprocesscell-cell signalingprocessdiet induced thermogenesisprocessfear responseprocessheat generationprocessintracellular signal transductionprocessnegative regulation of multicellular organism growthprocesspositive regulation of cAMP biosynthetic processprocesspositive regulation of cAMP-mediated signalingprocesspositive regulation of GTPase activityprocesspositive regulation of heart rate by epinephrine-norepinephrineprocesspositive regulation of the force of heart contraction by epinephrine-norepinephrineprocessresponse to coldprocesstemperature homeostasisprocessvasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure
id:BE0000694
name:Beta-2 adrenergic receptor
organism:Humans
action:antagonist
Rait JL: Systemic effects of topical ophthalmic beta-adrenoceptor antagonists. Aust N Z J Ophthalmol. 1999 Feb;27(1):57-64.
known-action:unknown
name:Beta-2 adrenergic receptor
general-function:Protein homodimerization activity
specific-function:Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
gene-name:ADRB2
locus:5q31-q32
cellular-location:Cell membrane
transmembrane-regions:35-58 72-95 107-129 151-174 197-220 275-298 306-329
signal-regions:
theoretical-pi:7.44
molecular-weight:46458.32
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:286GenAtlasADRB2GenBank Gene DatabaseY00106GenBank Protein Database29371IUPHAR29Guide to Pharmacology29UniProtKBP07550UniProt AccessionADRB2_HUMAN
synonyms:ADRB2RB2ARBeta-2 adrenoceptorBeta-2 adrenoreceptor
amino-acid-sequence:>lcl|BSEQ0037061|Beta-2 adrenergic receptor MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAK FERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTAS IETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQE AINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRF HVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNT GEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL
gene-sequence:>lcl|BSEQ0020478|Beta-2 adrenergic receptor (ADRB2) ATGGGGCAACCCGGGAACGGCAGCGCCTTCTTGCTGGCACCCAATAGAAGCCATGCGCCG GACCACGACGTCACGCAGCAAAGGGACGAGGTGTGGGTGGTGGGCATGGGCATCGTCATG TCTCTCATCGTCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCCATTGCCAAG TTCGAGCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTGTGCTGATCTG GTCATGGGCCTGGCAGTGGTGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGTGGACT TTTGGCAACTTCTGGTGCGAGTTTTGGACTTCCATTGATGTGCTGTGCGTCACGGCCAGC ATTGAGACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTACTTCACCTTTCAAG TACCAGAGCCTGCTGACCAAGAATAAGGCCCGGGTGATCATTCTGATGGTGTGGATTGTG TCAGGCCTTACCTCCTTCTTGCCCATTCAGATGCACTGGTACCGGGCCACCCACCAGGAA GCCATCAACTGCTATGCCAATGAGACCTGCTGTGACTTCTTCACGAACCAAGCCTATGCC ATTGCCTCTTCCATCGTGTCCTTCTACGTTCCCCTGGTGATCATGGTCTTCGTCTACTCC AGGGTCTTTCAGGAGGCCAAAAGGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTC CATGTCCAGAACCTTAGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGA TCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCATGGGC ACTTTCACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTGATCCAGGAT AACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCTATGTCAATTCTGGT TTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTCAGGATTGCCTTCCAGGAGCTTCTG TGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATGGCTACTCCAGCAACGGCAACACA GGGGAGCAGAGTGGATATCACGTGGAACAGGAGAAAGAAAATAAACTGCTGTGTGAAGAC CTCCCAGGCACGGAAGACTTTGTGGGCCATCAAGGTACTGTGCCTAGCGATAACATTGAT TCACAAGGGAGGAATTGTAGTACAAATGACTCACTGCTGTAA
pfams:PF000017tm_1
go-classifiers:componentapical plasma membranecomponentaxoncomponentdendritic spinecomponentearly endosomecomponentendosomecomponentintegral component of plasma membranecomponentlysosomecomponentneuronal cell body membranecomponentnucleuscomponentplasma membranecomponentreceptor complexcomponentsarcolemmafunctionbeta2-adrenergic receptor activityfunctiondopamine bindingfunctiondrug bindingfunctionepinephrine bindingfunctionnorepinephrine bindingfunctionpotassium channel regulator activityfunctionprotein homodimerization activityprocessactivation of adenylate cyclase activityprocessactivation of transmembrane receptor protein tyrosine kinase activityprocessadenylate cyclase-activating adrenergic receptor signaling pathwayprocessadenylate cyclase-modulating G-protein coupled receptor signaling pathwayprocessagingprocessassociative learningprocessbone resorptionprocessbrown fat cell differentiationprocesscell surface receptor signaling pathwayprocesscell-cell signalingprocesscellular response to hypoxiaprocessdesensitization of G-protein coupled receptor protein signaling pathway by arrestinprocessdiaphragm contractionprocessdiet induced thermogenesisprocessendosome to lysosome transportprocessestrous cycleprocessexcitatory postsynaptic potentialprocessfemale pregnancyprocessheat generationprocessliver regenerationprocessmitophagy in response to mitochondrial depolarizationprocessnegative regulation of angiogenesisprocessnegative regulation of inflammatory responseprocessnegative regulation of multicellular organism growthprocessnegative regulation of ossificationprocessnegative regulation of platelet aggregationprocessnegative regulation of smooth muscle contractionprocessnegative regulation of urine volumeprocesspositive regulation of apoptotic processprocesspositive regulation of ATPase activityprocesspositive regulation of autophagosome maturationprocesspositive regulation of bone mineralizationprocesspositive regulation of cell proliferationprocesspositive regulation of lipophagyprocesspositive regulation of MAPK cascadeprocesspositive regulation of potassium ion transportprocesspositive regulation of protein ubiquitinationprocesspositive regulation of skeletal muscle tissue growthprocesspositive regulation of sodium ion transportprocesspositive regulation of the force of heart contraction by epinephrineprocesspositive regulation of transcription from RNA polymerase II promoterprocesspositive regulation of vasodilationprocessreceptor-mediated endocytosisprocessregulation of calcium ion transportprocessregulation of sensory perception of painprocessresponse to coldprocessresponse to dexamethasoneprocessresponse to estrogenprocessresponse to monoamineprocessresponse to progesteroneprocessresponse to testosteroneprocesssynaptic transmission, glutamatergicprocessvasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressureprocesswound healing

酶

BE0002433Cytochrome P450 1A2HumanssubstrateL4582Betaxolol, Pediatric Care Solutionshttps://pediatriccare.solutions.aap.org/drug.aspx?gbosid=171921F1635CYp1A3 CTEP document, cancer.gov//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/635/original/cyp1a2.doc?1537809665F1636Companion Dx reference lab document: EXPANDED TEST OFFERING IN PHARMACOGENOMICS: CYP1A2//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/636/original/PGX_CYP1A2_V11.15.pdf?1537809788unknownCytochrome P450 1A2Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.CYP1A215q24Endoplasmic reticulum membrane9.4358293.7615HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2596GenAtlasCYP1A2GenBank Gene DatabaseZ00036Guide to Pharmacology1319UniProtKBP05177UniProt AccessionCP1A2_HUMAN1.14.14.1Cholesterol 25-hydroxylaseCYPIA2Cytochrome P(3)450Cytochrome P450 4Cytochrome P450-P3>lcl|BSEQ0004778|Cytochrome P450 1A2 MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN>lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2) ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGAPF00067p450componentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunctionaromatase activityfunctioncaffeine oxidase activityfunctiondemethylase activityfunctionelectron carrier activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenprocessalkaloid metabolic processprocessarachidonic acid metabolic processprocesscellular respirationprocesscellular response to cadmium ionprocessdibenzo-p-dioxin metabolic processprocessdrug catabolic processprocessdrug metabolic processprocessepoxygenase P450 pathwayprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesshydrogen peroxide biosynthetic processprocesslung developmentprocessmethylationprocessmonocarboxylic acid metabolic processprocessmonoterpenoid metabolic processprocessomega-hydroxylase P450 pathwayprocessoxidation-reduction processprocessoxidative deethylationprocessoxidative demethylationprocessporphyrin-containing compound metabolic processprocesspost-embryonic developmentprocessregulation of gene expressionprocessresponse to estradiolprocessresponse to immobilization stressprocessresponse to lipopolysaccharideprocesssmall molecule metabolic processprocesssteroid catabolic processprocesstoxin biosynthetic processprocessxenobiotic metabolic processBE0002363Cytochrome P450 2D6HumanssubstrateA3922517635183Zateyshchikov DA, Minushkina LO, Brovkin AN, Savel'eva EG, Zateyshchikova AA, Manchaeva BB, Nikitin AG, Sidorenko BA, Nosikov VV: Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol. 2007 Aug;21(4):437-43. doi: 10.1111/j.1472-8206.2007.00518.x.A3441525341854Zisaki A, Miskovic L, Hatzimanikatis V: Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des. 2015;21(6):806-22.unknownCytochrome P450 2D6Steroid hydroxylase activityResponsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.CYP2D622q13.1Endoplasmic reticulum membrane7.2655768.9422HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2625GenAtlasCYP2D6GenBank Gene DatabaseM20403GenBank Protein Database181350Guide to Pharmacology1329UniProtKBP10635UniProt AccessionCP2D6_HUMAN1.14.14.1Cholesterol 25-hydroxylaseCYP2DL1CYPIID6Cytochrome P450-DB1Debrisoquine 4-hydroxylase>lcl|BSEQ0004641|Cytochrome P450 2D6 MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV FAFLVSPSPYELCAVPR>lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6) ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG GACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG CCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG TTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG CTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC CGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC CTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC AACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT TGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA GCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT CGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG CGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC CTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG ACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG AAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT GACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC ATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG CAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT CATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA TCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC CTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC CGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG CTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC TTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAGPF00067p450componentcytoplasmcomponentendoplasmic reticulumcomponentendoplasmic reticulum membranecomponentmitochondrionfunctionarachidonic acid epoxygenase activityfunctionaromatase activityfunctiondrug bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenfunctionoxygen bindingfunctionsteroid hydroxylase activityprocessalkaloid catabolic processprocessalkaloid metabolic processprocessarachidonic acid metabolic processprocesscoumarin metabolic processprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocessisoquinoline alkaloid metabolic processprocessmonoterpenoid metabolic processprocessnegative regulation of bindingprocessnegative regulation of cellular organofluorine metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid metabolic processprocessxenobiotic metabolic process

载体

运输工具

药物反应

效应

不良反应